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ABSTRACT
The proper maintenance of the pathways governing cell growth is critical to
ensure cell survival and DNA fidelity. Much of our understanding of how the cell
cycle is regulated comes from studies examining the relationship between DNA
viruses and the mechanisms of cell proliferation control. There are numerous
examples demonstrating that viruses can alter the host cell environment to their
advantage. In particular, the small DNA tumor viruses , which include adenovirus
simian-virus 40 (SV-40), and human papillomavirus (HPV), can modulate the host
cell cycle to facilitate viral DNA replication. Due to the fact that these viruses infect
quiescent , non-cycling cells and lack the necessary enzymes and resources to
replicate their DNA (e.g. DNA polymerase), the small DNA tumor viruses must
activate the host cell replication machinery in order to expedite viral DNA replication.
The capacity of these viruses to perturb normal cell proliferation control is dependent
upon their oncogene products , which target p53 and members of the
Retinoblastoma (RB) family of proteins and inactivate their respective functions. By
targeting these key cell cycle regulatory proteins , the small DNA tumor viruses
induce the infected host cells to enter S-phase and activate the components
involved with host cell DNA synthesis thereby generating an environment that is
conducive to viral DNA replication.
In contrast , the larger, nuclear-replicating DNA viruses such as those from the
family Herpes virida e do not share the same stringent requirement as the small DNA
viruses to induce the infected host cell to enter S-phase. The herpesviruses encode
vii
many of the components to stimulate nucleotide biosynthesis and the necessary
factors to facilitate virus DNA replication including a viral DNA polymerase and other
accessory factors. Additionally, many herpesviruses encode gene products that
arrest the host cell cycle , in most instances , prior to the G /S transition point.
Inducing cells to growth arrest appears to be a prerequisite for the replication of
most herpesviruses.
However, in addition to encoding factors that inhibit the cell cycle
, many
herpesviruses encode proteins that can promote cell cycle progression in a manner
similar to the small DNA tumor virus oncoproteins. By targeting members of the RB
family and p53 protein , the herpesvirus proteins induce S-phase and activate S-
phase associated factors that playa role in DNA replication. In this manner, the
herpesviruses may promote an environment that is favorable for DNA replication.
Consistent with the other herpesviruses
, human cytomegalovirus (HCMV)
induces human fibroblasts to growth arrest. However
, in other cell types , virus
infection causes cells to enter S-phase. In addition , HCMV replication requires
several cellular factors that are present only during S-phase. Furthermore , HCMV
induces the activation of S-phase-associated events as well as the increased
expression of numerous S-phase genes following infection.
HCMV encodes two immediate early (IE) gene products
, IE1-72 and IE2-
which can interact with members of the RB family of proteins. Additionally, the IE2-
86 protein can bind to and inhibit p53 protein function. Given the functional
resemblance between the HCMV IE proteins and the oncoproteins of the small DNA
viii
tumor viruses , we hypothesized that expression of the HCMV IE proteins could
modulate cell cycle control.
Specifically, we determined that expression of either IE1-72 or IE2-86 can
induce quiescent cells to enter S-phase and delay cell cycle exit following serum
withdrawal. Moreover, IE2-86 mediates this effect in the presence or absence of
p53 , whereas IE1-72 fails to do so in p53-expressing cells. Furthermore
, both IE1-
72 and IE2-86 induce p53 protein accumulation that is nuclear localized.
Because IE 1-72 fails to promote S-phase entry in cells expressing p53 and
induces p53 protein levels
, the mechanism by which IE1-72 alters p53 levels was
examined. IE1-72 elevates p53 protein levels by inducing both 
p1gARF protein and
an ATM-dependent phosphorylation of p53 at Ser
. IE1-72 also promotes p53
nuclear accumulation by abrogating p53 nuclear shuttling. As consequence 
of this
IE1-72-mediated increase in p53 levels
, p21 protein is induced leading to a p21-
dependent growth arrest in cells expressing IE1-72.
These findings demonstrate that the HCMV IE proteins can alter cell
proliferation control and provide further support to the notion that HCMV
, through the
expression of its IE proteins
, induces S-phase and factors associated with S-phase
while blocking cell DNA synthesis
, to possibly generate an environment that is
suitable for viral DNA replication.
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CHAPTER I
Introduction
A. The Family Herpesviridae
The herpesviruses are large DNA viruses that are distributed in nature.
The herpesvirus virion is comprised of four concentric layers: (1) an inner core
containing the viral DNA in the form of a torus , surrounded by (2) an icosahedral
capsid , an amorphous structure referred to as (3) the tegument, and a (4) lipid-
i .
protein envelope. The herpesviruses contain linear , double stranded DNA that
ranges in length from 120 to 250 kbp (121).
All of the herpesviruses share several properties that are distinct for this
family of viruses. Each herpesvirus encodes most of the factors they require to
increase the pool of deoxyribonucleotides and to synthesize their DNA. Viral
DNA synthesis and capsid assembly occur in the nuclei of herpesvirus-infected
cells (159). A productive herpesvirus infection results in the destruction of the
infected cell.
Another feature of the herpesviruses is their ability to establish latent
infections within their host for an indefinite period of time. The viral genomes
likely persist in the form of episomes within the nuclei of the infected host cell.
The latent herpesviruses express a certain subset of latency-associated genes
and retain the capacity to replicate and cause disease upon activation (121).
The herpesviruses vary in their host-cell specificity, replication kinetics , speed at
which they lyse cells , and the cells that they latently infect.
The family Herpesviridae is divided into three subfamilies:
alphaherpesviruses , betaherpesviruses , and gammaherpesviruses (100). The
alphaherpesviruses infect a wide host range , grow rapidly, and establish latency
in sensory ganglia (122). This subfamily includes herpes simplex virus (HSV).
The betaherpesviruses , on the other hand , have a restricted host range and
replicate much slower than the alphaherpesviruses. Examples of the
betaherpesviruses include both human and murine cytomegaloviruses and these
viruses can establish latency at numerous sites including Iymphoreticular tissue
secretory glands , kidneys , and other tissues (159). The gammaherpesviruses
target cells of lymphoid origin. Specifically, they infect T- or B-Iymphocytes and
establish latency in lymphoid tissue (121). Members of this subfamily include
Epstein-Barr virus (EBV) and Kaposi's sarcoma associated Herpesvirus (KSHV)
(100).
B. Cytomegalovirus
1. Human Cytomegalovirus
Human cytomegalovirus (HCMV) is a ubiquitous , species-specific beta-
herpesvirus that, like other herpesviruses , can establish life- long latency in its
host following primary infection. The HCMV genome consists of a linear, double-
stranded DNA that is 230,000 base pairs in length , which is encased within an
icosahedral capsid and surrounded by tegument and a lipid bilayer envelope
containing numerous HCMV-encoded glycoproteins (102) (Figure 1. 1). The
HCMV genome encodes for over 200 open reading frames (ORFs), and is
divided into two covalently linked segments , designated U (unique long) and Us
(unique short), which are flanked by inverted repeat sequences (Figure 1. 2).
HCMV , like other betaherpesviruses , is highly species-specific and will
therefore only productively infect human cells , preferably those of fibroblast
origin. Unlike the other herpesviruses , HCMV has a slow replicative cycle (::24
h) and requires a longer period of time to induce its cytopathic effects (102).
HCMV- infected cells typically become enlarged (cytomegalia) and eventually
develop nuclear and cytoplasmic inclusions that are characteristic of HCMV
infection (113). In vivo the virus targets a wide variety of cells including epithelial
and endothelial cells , fibroblasts , smooth muscle cells , and peripheral blood
leukocytes , which include monocytes and granulocytes (133).
2. Epidemiology
Although the virus is endemic within the population , HCMV infection rarely
causes symptomatic disease in healthy, immunocompetent individuals but
manifests itself as a lifelong persistent infection. The reactivation of HCMV
commonly occurs in immunocompromised and immunosuppressed individuals
and is the causative agent of a variety of maladies such as HCMV-associated
pneumonitis and retinitis , which are the most prevalent HCMV-associated
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Figure 1.1. Ilustration of HCMV virion and structural organization.
Figure acquired from the following website: http://www. bioqrafix.de/ Reproduced
with permission from Dr. Marko Reschke.
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Figure 1.2. Diagram ilustrating the organization of the HCMV genome.
The HCMV genome consists of linear double stranded DNA that is divided into
two covalently linked segments
, designated U , (unique long) and U , (unique
short). The DNA segments are flanked by inverted repeat sequences (depicted
as: a , an , a , b , b' , c , and c).
problems , detected in these patients (113). Additionally, reactivation of latent
HCMV or transmission of the virus to organ transplant recipients may result in
complications such as disseminated viremia and in some instances
, organ
dysfunction. HCMV also poses a serious threat to the health of HIV-positive
individuals because HCMV may accelerate the development of AIDS as well as
contribute to the morbidity associated with increased immunodeficiency (113).
Likewise , HCMV infection is problematic for pregnant women and children
especially infants. HCMV is recognized as the most common congenital viral
infection and is the leading cause of various neurological abnormalities
associated with an infectious agent during early childhood (61). Infants
congenitally infected with HCMV are more prone to hearing loss
, chorioretinitis
and other disorders involving the perceptual organs (e.g. inner ears and eyes)
and the central nervous system.
3. Association with proliferative disease
There is a plethora of evidence that suggests a link between HCMV and a
number of proliferative disorders. Although HCMV does not appear to be
oncogenic, HCMV exhibits the capacity to transform rodent embryo fibroblasts (6
15) and in some instances
, human cells (48) in vivo. Additionally, the detection
of HCMV DNA and antigen in tumor tissues isolated from patient biopsies along
with elevated HCMV antibody titers in these patients imply a relationship
between HCMV and several cancers including cervical carcinoma
, prostate
cancer, and adenocarcinoma of the colon (37
, 130). However, it is unlikely that
HCMV directly induces cancer since the low incidence rates observed for each
the cancers linked to the virus do not reflect the ubiquitous nature of HCMV
within the population. It has been suggested that HCMV may act as a co-
etiologic agent in the development of tumors through a "hit and run" mechanism
(90 , 131) in which HCMV promotes cellular transformation by causing genetic
instability or by preventing cells from undergoing apoptosis. Thus it appears that
HCMV may contribute to tumor formation
, but its specific role in the
transformation process remains undefined.
In contrast to human cancer
, a more apparent relationship between HCMV
and atherosclerosis exists. Atherosclerosis is characterized by the formation of
fibrous fatty lesions along blood vessel walls accompanied by inflammation (123)
resulting in the occlusion of blood flow in the affected vessel. Several lines of
evidence hint at a contributory role for HCMV in the atherosclerosis process.
The results from numerous epidemiological studies show that atherosclerosis
patients exhibit high levels of anti-HCMV antibodies and that HCMV-seropositive
individuals are more susceptible to developing vascular disease (1
, 52 , 97 , 137).
Additionally, HCMV induces several events that may accelerate the
atherosclerotic process. HCMV increases the expression of scavenger receptors
in smooth muscle cells (SMCs) leading to increased lipid accumulation (138
172). Also , HCMV infection of endothelial cells induces the expression of several
chemokines and adhesion molecules that enhance the migration and adherence
of inflammatory cells to the endothelium (7
, 143). Moreover, detection of viral
DNA and antigen in fibrous lesions and in cells present in fatty streaks
(endothelial cells and SMCs) (98
, 112), as well as in the arterial walls of coronary
artery disease patients (60
, 64), imply that HCMV presence may be a factor in
atherosclerosis development.
Recent evidence suggests that HCMV may also playa role in the
development of restenosis
, a coronary artery disorder that is characterized by the
overproliferation , migration , and accumulation of arterial SMCs along the vessel
wall following coronary angioplasty (139
, 140). In contrast to atherosclerosis , the
occlusion resulting from the accumulation of SMCs is often worse than the initial
blockage. The detection of viral DNA and protein in SMCs from restenotic
lesions suggests an association between HCMV presence and restenosis.
Additionally, epidemiological evidence suggests that a correlation exists between
HCMV-seropositivity and restenosis occurrence. HCMV-seropositive patients
exhibit a higher propensity of developing restenosis following coronary
angioplasty as compared to HCMV-seronegative patients (173). Moreover
studies using rat CMV in a rodent carotid artery model demonstrate that the rates
of restenosis following angioplasty are higher in rat CMV- infected animals as
compared to uninfected ones (174).
Although there is no definitive proof that HCMV causes restenosis
, it has
been hypothesized that the virus promotes certain events that contribute to
restenosis. HCMV infection enhances SMC migration in vitro (175). This effect
may be attributed to the increased expression of various chemokines such as
RANTES , monocyte chemoattractant protein- 1 (MCP- 1), and interleukin-8 (IL-
by HCMV- infected endothelial cells and SMCs (99 , 143 , 148). HCMV infection of
endothelial cells also induces the expression of surface adhesion molecules that
augment the migration and adhesion of SMCs and inflammatory cells to the
endothelium (143). In addition , HCMV encodes a chemokine receptor (Us28)
that when expressed on the surface of SMCs, promotes their cellular migration 
vitro (148). Taken together, these findings imply a strong link between HCMV
and the induced migration of SMCs that may contribute to restenosis.
In contrast to our understanding of HCMV and SMC migration , the
relationship between HCMV and the overproliferation of SMCs remains vague.
Studies examining HCMV effect on cellular proliferation have yielded conflicting
results. Early studies on HCMV and the cell cycle suggested that HCMV- infected
cells exhibit increased rates of DNA synthesis (5 , 51). Notably, HCMV infection
induces proliferation in SMCs in vitro that may be attributed in part, to the HCMV-
mediated increase in NFxB activity and platelet-derived growth factor (PDGF)
receptor in these cells (141 , 175). Additionally, HCMV inhibits apoptosis 
response to various stimuli (90 , 176). In this manner, HCMV may contribute to
the development of restenosis by promoting the overproliferation of SMCs in vivo
and abrogating their ability to undergo apoptosis. However , contrary to the
proliferative effects mediated by the virus , HCMV infection causes human
fibroblasts , the model system for HCMV research , to undergo growth arrest (19
;,.
, 69 , 88). Given the divergent effects that HCMV mediates on the cell cycle , it
remains unclear if HCMV contributes to the overproliferation of SMCs in vivo and
this brings into question the issue of how HCMV alters the cell cycle in general.
C. Viruses and the cell cycle
1. Targeting of the RB proteins by the small DNA tumor viruses
There is a precedent for DNA viruses altering cell cycle control to their
advantage. In particular, the small DNA tumor viruses , such as adenovirus
simian virus 40 (SV-40), and human papillomavirus (HPV), can each perturb the
replication machinery of the host cell to facilitate the replication of their viral DNA
(121). Their ability to overcome the normal regulation of cell proliferation control
is dependent upon their oncogene products , which target and inactivate
members of the RB family of proteins. The RB protein family consists of three
members , p107 , p130 , and pRb , whose function is to maintain cells in a
quiescent state as well as regulate the transition from G to S-phase by
modulating the activity of the E2F family of transcription factors (56). The E2F
proteins play an essential role in regulating the expression of genes required for
DNA replication (151). Active hypophosphorylated RB proteins repress both E2F
activity and the expression of E2F target genes by binding to E2F proteins at
their C-terminal transactivation domain and recruiting transcriptional repressors
(56). When the RB proteins become hyperphosphorylated by cyclin/cyclin-
dependent kinase complexes activated during mid- late G , the RB proteins no
longer bind E2F proteins resulting in the derepression of E2F target genes (109).
Each of the small DNA tumor viruses encodes proteins that can bind to
the RB proteins , displace their interaction with E2F , and alleviate the repression
of E2F proteins. The E1A protein of adenovirus , large T antigen of SV- , and
the E7 protein of HPV each contain an LxCxE motif that facilitates their binding to
the RB "pocket domain" thereby displacing E2F proteins from their interaction
with the RB proteins at this region (108). The displacement of the E2F proteins
from the RB proteins enables them to transactivate the promoters of their target
genes , including genes required for S-phase (32 , 81). Because each of the small
DNA tumor viruses infect quiescent cells and lack certain components needed to
replicate their viral DNA, it is thought that targeting the RB proteins allows for the
induction of S-phase genes thereby generating an environment conducive to viral
DNA replication.
2. Targeting of p53 protein by the small DNA viruses
In response to aberrant growth signals or cellular stresses , such as viral
infection , DNA damage , or hypoxia , the p53 protein becomes activated (118).
Mutations within the p53 gene that results in loss of p53 activity are detected in
almost half of all human tumors (153). Additionally, many tumors that contain
wild-type p53 often contain mutations in the pathways that regulate p53 protein
levels and activity. Further evidence that p53 is an important tumor suppressor is
that p53- mice rapidly develop tumors when compared to their wild-type
littermates (36). The p53 tumor suppressor protein is a sequence-specific DNA
binding transcription factor that transactivates the promoters of many p53-
responsive target genes including the cyclin-dependent kinase inhibitor p21
mediate cellular growth inhibition (41 , 57). Besides inducing growth arrest , p53
activation results in apoptosis (154).
In addition to the viral oncoproteins that target the RB family members
each of the small DNA tumor viruses express proteins that complex with and
inactivate p53 to prevent an infected cell from undergoing p53-mediated growth
arrest or apoptosis. The adenovirus E1 B 55kDa protein and the large T antigen
of SV-40 bind p53 and inhibit its function (11 , 87 , 96 , 126 , 163). In contrast , the
HPV E6 protein promotes the degradation of p53 through the ubiquitin-
dependent proteolytic system (128). In all of these instances , expression of the
viral oncoproteins alters p53 function and/or levels within infected cells to
override this host response to virus infection. Thus , the abiliy to disrupt RB-
mediated repression of E2F and abrogate p53 activity facilitates the DNA
replication of each of the small DNA tumor viruses.
3. Large DNA viruses
The larger, nuclear replicating DNA viruses such as the herpesviruses
seem to mediate a different effect on the cell cycle as compared to the small
DNA tumor viruses. In contrast to the small DNA tumor viruses , the
herpesviruses have evolved a replication process that does not appear to require
an S-phase- like environment. All of the herpesviruses encode enzymes and
factors that are involved in enhancing the pool of available deoxyribonucleotides
within the infected host cell (121). The herpesviruses also encode a viral DNA
polymerase as well as accessory proteins that playa role in viral DNA 
replication.
Furthermore , many of the herpesviruses encode proteins that cause cells to
growth arrest. Therefore , it appears that inducing cell cycle arrest within the
infected host cell is an integral part of the herpesvirus replication strategy.
HCMV has been shown to have varying effects on the cell cycle. Some
studies show that HCMV infection stimulates cellular DNA synthesis (5
, 142). In
contrast to these observations
, many studies on HCMV effects on the cell cycle
show that HCMV induces a G
, and occasionally a G , growth arrest in
infected human fibroblasts (19
, 35 , 69 , 88). Although these more recent studies
demonstrate that HCMV induces fibroblasts to undergo what has been described
as a " arrest" , biochemically these cells exhibit hallmarks of early S-phase
entry including pRb hyperphosphorylation
, increased E2F transcriptional activity,
elevated cyclin E and cyclin A kinase activity, and expression of many S-phase
genes such as dihydrofolic reductase (DHFR), DNA polymerase alpha
proliferating cell nuclear antigen (PCNA), topoisomerase II
, ORC 1 , and the
minichromosome maintenance (MCM) proteins 3-7 (19 , 35 , 70). In addition
HCMV infection of human endothelial cells
, rodent smooth muscle cells , or a
differentiated monocytic cell line biases these cells towards S-
phase (132 , 175).
. -
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These observations suggest that HCMV mediates differing effects on the cell
cycle.
The ability of HCMV to manipulate the cell cycle may be attributed to its
ability to modulate the activities of certain cell cycle regulatory proteins. Besides
altering the levels of phosphorylated pRb and inducing E2F transcription
activation function , HCMV increases p53 levels by decreasing p53 degradation to
enhance its stability in infected cells (44 , 69). Additionally, HCMV sequesters p53
into distinct foci within the nuclei of infected cells (44). HCMV also promotes the
nuclear localization of Cdk2 and stimulates Cdk2 activity in infected cells
, which
is necessary for HCMV replication (18 , 20). This increase in Cdk2 activity 
attributed in part to the HCMV-mediated degradation of p21 (27). Furthermore , it
has been hypothesized that HCMV modulates the proteins that regulate the cell
cycle through its immediate early (IE) proteins.
D. HCMV immediate early proteins
1. General background
Analogous to the other members of the family Herpesviridae expression
of HCMV genes occurs in a temporal order. The first set of viral gene products to
be expressed is classified as immediate early, followed by the expression of the
early genes , and finally, the late gene products (121). The IE genes do not
require de novo protein synthesis for their expression. The most abundantly
transcribed HCMV IE gene products originate from ORFs encoded in the major
, . ::..
IE region located within the U segment of the viral genome and that are under
the control of the major IE promoter (MIEP) (157). Transcription from the MIEP
gives rise to several spliced mRNA species (Figure 1.3) (144). The initial and
most abundant transcript originates from the 123 region and gives rise to a
spliced 1. 95 kb mRNA composed of exons 1 through 4 and encodes a 491 aa
(72 kDa) nuclear phosphoprotein referred to as IE1-72 (also known as IE1 or
IE72) (146). Transcription through the other IE gene 122, gives rise to two
major transcripts , a 2.25 and a 1.7 kb mRNA, that have the same first three
exons as IE1-72 mRNA but contain a novel exon , exon 5 , in place of exon 4 as a
result of alternative splicing (145). The 2.25 kb mRNA encodes a 579 aa (82-
kDa) nuclear protein , IE2-86 (also known as IE2 or IE86), and the 1. 7 kb mRNA
encodes for a 425 aa (55 kDa) protein , IE2-55 (also known as IE55). IE2-55 is
identical to IE2-86 except for a 154 aa deletion between residues aa 365 and 519
resulting from a splicing event within exon 5 (77). Because all three of the HCMV
IE proteins contain the same first three exons , they all share the same 85 aa in
their N-terminal sequence (144) (Figures 1.4 and 1.5). However, the remaining
sequences in each of the IE proteins differ and likely account for the divergent
activities exhibited by each protein.
2. HCMV IE1-
IE1-72 mRNA is the initial and most abundant viral transcript expressed
during HCMV infection (146). Studies utilizing HCMV IE1-72-deletion mutants
Ul123.1-122
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Figure 1.3. HCMV major IE proteins and their location within the genome.
Schematic diagram representing the organization of the HCMV DNA genome
and the relative position of the ORFs encoding the major IE gene products. The
major IE transcripts are expressed from the major IE promoter (MIEP; shown in
box with vertical lines) and are alternatively spliced to yield the major IE proteins.
Arrows represent transcripts and broken lines depict splicing events/sites.
show that IE1-72 is not absolutely required for HCMV infectivity and viral DNA
replication (53 , 101), but does contribute to the efficient replication of HCMV.
IE1-72 primarily functions as a transcriptional co-activator of numerous HCMV
gene promoters (53 67). The contribution of IE1-72 to HCMV replication most
likely revolves around its ability to transactivate the expression of early viral
genes that facilitate the replication process. Additionally, IE1-72 activates
expression from its own promoter, the MIEP , through the induction of NFKB (28
83).
In addition to viral promoters , IE1-72 activates the expression of several
cellular gene promoters. A region located in the C-terminus of IE1-72 is
necessary for IE1-72 transcriptional co-activation (ref) (Figure 1.4). Although
IE1-72 does not bind to DNA directly, the transient expression of IE1-72 is
sufficient to stimulate transcription from a number of TATA-Iess promoters
including the cellular DHFR and DNA polymerase alpha promoters
, in addition to
certain promoters containing TATA-box elements (59 156). IE1-
expression enhances AP-1 activity and is sufficient to induce AP- driven
transcription in reporter constructs (79). Moreover
, IE1-72 contributes to the
induction of Rel/NF-KB transcription by interacting with the transcription factor
Sp- 1 to enhance p65 promoter transactivation (164
, 165).
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Figure 1.4. The HCMV IE1-72 protein and its regulatory domains.
Schematic diagram of HCMV IE1-72 and location of the functional and protein
binding domains. Note that many of the functional domains have only been
grossly mapped. Mapping of some functional domains are still unclear. Motif
abbreviations: Zn , zinc finger; LZ , leucine zipper; LR , leucine-rich; AD , acidic
domain.
3. HCMV IE2-
The importance of the IE2-86 protein to HCMV replication is exemplified
by the inability to generate infectious HCMV mutants lacking IE2-86. The results
from several alternative approaches to assess the role of IE2-86 in HCMV
replication show that IE2-86 is essential for virus production (93). The failure of
HCMV to replicate in the absence of IE2-86 is consistent with its role as a potent
transactivator of numerous viral early genes including UL 112/113 and others that
participate in viral replication (67). In addition to activating the expression of
HCMV early and late genes , IE2-86 can transactivate other viral promoters such
as the HIV- 1 L TR (156 , 162).
IE2-86 can transactivate the promoters of many cellular genes. Some 
this transactivation occurs through a TATA-box-dependent mechanism that
involves the interaction of IE2-86 with components of the basal transcription
complex including the TATA box-binding protein (TBP), TFII , and TFIID (24 , 55
, 73) (Figure 1.5). Additionally, IE2-86 exhibits TBP associated factor (TAF)-
like activity as demonstrated by the rescue of cells containing defective T 
proteins by IE2-86 (91).
Besides functioning as a strong transactivator , IE2-86 contains a domain
that allows it to function as a repressor that downregulates expression from the
MIEP by binding to the so-called cis-repression sequence (crs) that lies within the
MIEP (114) (Figure 1. 5). The fact that IE2-86 induces the expression of several
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Figure 1.5. The HCMV IE2-86 protein and its regulatory domains.
Schematic diagram of HCMV IE2-86 and location of the functional and protein
binding domains. Note that many of the functional domains have only been
grossly mapped. Mapping of some functional domains are still unclear (e.g. pRb
binding). HLH helix-loop-helix domain.
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viral and cellular genes while auto-regulating its own expression implies multiple
roles for IE2-86 in relation to regulating gene expression during the viral infection
process.
4. HCMV IE2-
The IE2-55 gene product is encoded by a transcript that is a splice variant
of the IE2-86 gene product and contains a conserved N-terminus as well as a
155aa deletion at aa 365-519 in the C-terminus. The region that is deleted has
been shown to be required for many of the functions attributed to IE2-
including transcriptional activation and DNA binding (29 , 92 , 115 , 129).
Consequently, unlike IE2- , IE2-55 fails to transactivate HCMV early promoters
and to repress the MIEP at the crs (80). Additionally, IE2-55 fails to dimerize with
IE2-86 (29) and the inability of IE2-55 to dimerize may contribute to its failure to
transactivate the promoters of HCMV early genes.
5. HCMV IE proteins and the cell cycle
In addition to their ability to enhance the transcription of viral and cellular
gene promoters , the HCMV IE proteins modulate components of the cell cycle
machinery. Both IE1-72 and IE2-86 exhibit similar properties to the small DNA
tumor virus oncoproteins in that the IE proteins target members of the RB family
of proteins. However, unlike the E1A, large T antigen , and E7 proteins , the
HCMV IE proteins lack the consensus pocket domain-binding motif, LxCxE , and
therefore , do not bind to the RB proteins at their pocket domains (43 , 54 , 71).
Moreover, in contrast to the viral oncoproteins , which target all three RB family
members , the HCMV IE proteins bind to specific RB family members , IE1-
binds p1 07 and IE2-86 interacts with pRb (43 , 54 , 116).
The interaction between IE1-72 and p107 occurs through a domain
contained within the first 85 aa of the N-terminus of IE1-72 (Figure 1.4) (71 , 116).
Binding of IE1-72 to p107 alleviates the p107-mediated repression of E2F-
responsive promoters and abrogates p107-mediated growth suppression (116).
Additionally, it has been suggested through in vitro kinase assays that IE1-72 can
exhibit kinase activity and phosphorylate p107 and p130 to disrupt their
interaction with E2F4 (111). A putative kinase domain has been identified on
IE1-72 spanning from aa 173 to 197 (Figure 1.4). Besides p107 and p130 , IE1-
72 phosphorylates the E2F proteins , E2F1 , E2F2 , and E2F3 in vitro (111) and
can interact with E2F1 (94), however the significance of these events to the cell
cycle is not known.
Analogous to IE1- , IE2-86 interacts with an RB family member, pRb (43
54). Attempts to map the pRb-binding domain have shown that several regions
on IE2-86 spanning from aa 85 to 364 can interact with pRb (Figure 1.5) (refs).
Binding of IE2-86 to pRb relieves the pRb-mediated repression of E2F
responsive promoters (43 , 54). However, the precise mechanism by which IE2-
86 blocks pRb function is unclear. IE2-86 induces the expression of numerous
E2F-target genes including factors associated with the bioenzymatic machinery
necessary for DNA replication. For example , IE2-86 induces an increase in the
mRNA levels of c-myc , cyclin E , cdk2 , E2F1 , ribonucleotide reductase 1 and 2
thymidine synthetase , MCM3 , and MCM7 (136). The results from this study
imply that IE2-86 disruption of pRb-E2F complexes may free E2Fs to
transactivate their target genes.
In addition to pRb , IE2-86 also interacts with p53 and p21 (132 , 140). The
domain identified on IE2-86 that interacts with p53 is contained within the first
135 aa of the N-terminus (Figure 1.5). IE2-86 binds to the N-terminus of p53 and
this interaction inhibits p53 transactivation activity (152). Studies to elucidate
IE2-86 effect on the cell cycle showed that IE2-86 blocks cell cycle progression in
(19 , 35 , 69 , 88). However, subsequent studies indicated that IE2-86 induces
cells to enter S-phase (105). The ability of IE2-86 to promote S-phase entry is
attributed in part to IE2-86 transactivation of the cyclin E promoter and induction
of E2F activity (17 136).
Despite the absence of the dimerization , DNA binding, and transactivation
domains , the putative pRb binding sites that were identified on IE2-86 (43 , 54)
are present on IE2-55. It is unclear whether IE2-55 mimics IE2-86 by binding to
pRb and consequently exhibiting similar effects on the cell cycle as IE2-86.
There is an additional line of evidence that suggests that IE2-55 may have the
capacity to affect similar aspects of the cell cycle. It has been shown that
transient expression of IE2-55 induces NF-KB levels by somehow transactivating
the p1 05/p50 promoter and enhancing the transactivation of the p65 promoter via
1'. 
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Sp-1 (164 165). In contrast to IE2- , expression of IE2-55 fails to enhance the
DNA binding activity of Sp-1. Therefore , it appears that IE2-55 cooperates with
Sp- 1 to transactivate the NF-KB promoter though a different mechanism.
Furthermore, one might predict that the induction of NF-KB by IE2-55 should
increase protection from apoptosis and for that reason contribute to a more
favorable environment for virus replication.
Besides targeting RB family members and p53 , the HCMV IE proteins
IE1-72 and IE2- , co- localize to sites in the nucleus referred to as nuclear
domain 10 (ND10) at which DNA replication , transcription , pre-mRNA splicing,
and ribosome assembly take place (3 , 66). Although the precise function of
these structures , also referred to as Qromyelocytic leukemia protein (PML)
Qncogenic gomains (PODs), is not known , there is a correlation between the
nuclear distribution of the ND10/PODs and normal cell growth (95). Under
normal conditions , the ND1 O/PODs appear as nuclear punctate bodies that are
present through most of the cell cycle except during mitosis. However , in
instances where a loss of cell growth control occurs , the nuclear distribution of
ND10/PODs is disrupted (95).
Evidence suggests that disruption of the ND1 O/PODs is necessary for
efficient viral DNA transcription and replication. In the case of adenovirus , SV-
, and herpes simplex virus- 1 (HSV- 1), viral DNA transcription initiates at the
ND10/PODs (65). Adenovirus and HSV- , along with HCMV , encode proteins
that co- localize with and disrupt the ND10/PODs. The HCMV IE1-72 protein can
1".
interact with and disrupt the ND1 O/PODs and can also promote the dispersal of
PML protein from these structures (Figure 1.4) (2 , 3). In contrast , IE2-86 co-
localizes with PML in the ND10/PODs but neither disrupts the ND10/PODs nor
induces the nuclear redistribution of PML (3 , 4). Although the IE proteins co-
localize with ND1 O/PODs and some of their associated proteins , the
consequences of these events on the cell cycle remains unclear.
D. Thesis Aims
The objective of this dissertation was to determine whether the HCMV IE
proteins could modulate the host cell cycle, presumably to promote an
environment conducive to viral DNA replication. Given the ability of HCMV IE1-
72 and IE2-86 to target specific RB family members for inactivation , and in the
case of IE2- , to bind to and inactivate p53 , it was hypothesized that these
HCMV IE proteins modulate the cell cycle in a manner similar to the small DNA
tumor virus oncoproteins. The data presented in this thesis confirm that these IE
proteins can alter the cell cycle. Specifically, the experiments in Chapter III
demonstrate that expression of these IE proteins can alter the cell cycle by
inducing quiescent cells to enter S-phase and by delaying cells from exiting the
cell cycle. The inability of IE1-72 to promote S-phase entry as well as delay cell
cycle exit in the presence of p53 prompted us to examine IE1-72 effect on p53
protein and activity. The experiments in Chapter IV address the multiple
pathways by which IE1-72 induces p53 protein accumulation and the results
i,,
described in Chapter V detail the consequences of the IE1-72-mediated induction
of p53 in cells. These findings provide further insight into the relationship
between the HCMV IE proteins and the cell cycle.
CHAPTER"
Materials and Methods
A. Cells
Cells from a rat embryo fibroblast cell line , REF52 , were maintained in
Dulbecco s modified Eagle medium (DMEM , GIBCO BRL), supplemented with
5% fetal bovine serum (FBS) (Hyclone , Inc. ), 5% fetal calf serum (FCS)
(Hyclone , Inc. ) and 1 % penicillin-streptomycin (GIBCO BRL). Early passage
wild-type (WT) as well as genetically matched p53- deficient (p53- mouse
embryo fibroblasts (MEFs) (passages 2- 7), MdmZI-;p53- MEFs , and SAOS-
were generous gifts from Stephen Jones (University of Massachusetts
, Medical
School Worcester, MA). The p19ARF MEFs were a generous gift from Charles
Sherr (St. Jude s Medical Center , Memphis , TN). Early passage p2r and
genetically matched WT MEFs were obtained from Tyler Jacks (Massachusetts
Institute of Technology, Boston , MA). Human embryonic lung fibroblasts (HELs)
were a generous gift from Eng-Sheng Huang (University of North Carolina
Chapel Hill , NC). All of the aforementioned MEFs , SAOS-2 cells , and HEL cells
were cultured in DMEM supplemented with 10% FBS and 1 % penicillin-
streptomycin. Human dermal fibroblasts from ataxia-telangiectasia patients
(GM03395C; AT) as well as age matched , normal dermal fibroblasts
(GM00316B; WT) were obtained from the Coriell Institute for Medical Research
(Camden , NJ). The AT and WT human fibroblasts were cultured in minimal
essential media supplemented with 15% FBS , essential and non-essential amino
acids , vitamins , and 1 % penicillin-streptomycin. All cells were incubated in a
incubator supplemented with 5% carbon dioxide (C0
B. Recombinant adenoviruses
A recombinant adenovirus encoding an HCMV (AD169) IE1-72 cDNA
under the control of the HCMV promoter/enhancer region from position -299 to
+69 (AdIE1-72) and a recombinant adenovirus encoding an HCMV (Towne) IE2-
86 cDNA under the control of the HCMV promoter/enhancer region from position
299 to +60 were kindly provided by Gary Hayward (Johns Hopkins University,
Baltimore , MD) (3). A recombinant adenovirus encoding an empty vector cDNA
was generated (81) and was used as a negative control in our experiments. A
recombinant adenovirus containing a galactosidase ( gal) expression cassette
under the control of the HCMV enhancer (Ad gal) (82) was also used as a
negative control in our experiments. An E2F-1 eDNA-encoding recombinant
adenovirus (AdE2F1) was used a positive control in our cell cycle analyses (81).
Recombinant adenoviruses encoding wild- type p53 cDNA (Adp53) (82) and a
mutant form of p53 containing mutations at all of its phosphorylation sites
(Adp53N/C) (8 , 120) were used in our heterokaryons assays. Viruses were
grown and titered in a human embryonic kidney cell line (293 cells) and
subsequently purified on cesium-chloride gradients (110). Virus titers
representing the number of infectious particles per unit of volume were
determined by immunohistochemical staining of the adenovirus hexon with an
anti-adenovirus antibody (Biodesign International).
C. Virus infections
Different multiplicities of infection (MOls) representing the number of viral
particles used to infect a specific cell population were used for the different
recombinant adenoviruses with optimal doses empirically determined. 
Prior to
infection , cells were washed with PBS and with serum-free DMEM. The
recombinant adenoviruses were diluted in serum-free DMEM supplemented with
penicillin and streptomycin and then added to the cells. Infections were
incubated at 37 C in 5% CO for 1 h with plates being rocked every 15 min. After
1 h , the viral inoculum was removed and replaced with DMEM containing the
appropriate serum concentration and the cells were cultured at 37
D. Cell cycle analysis
a. Bromodeoxyuridine (BrdU) incorporation
Cells were plated at sub-confluent densities onto 6-well plates (Falcon)
and cultured under normal conditions prior to infection with the recombinant
adenoviruses. For the cell cycle exit analysis , cells were subjected to serum
starvation by culturing in media containing low concentrations of serum post-
infection (p. i). For the S-phase induction experiments , cells were rendered
quiescent by serum starvation prior to infection. The conditions (serum
concentration and culture time) employed to induce quiescence were empirically
determined for each cell type examined. After infection
, cells were cultured
under the appropriate serum starvation conditions. At 12 h prior to 
harvesting,
cells were labeled with bromodeoxyuridine (BrdU) by adding BrdU (10""M final
concentration) to the culture medium. At different times p.
, the culture medium
was removed and the cells were washed twice with PBS. Cells were then fixed
in ethanol (90% final concentration) for 5 minutes at room temperature. Fixed
cells were washed twice with PBS then incubated in hydrochloric acid (HCI) (2N
final concentration) for 30 minutes at room temperature. Afterwards
, sodium
tetra borate (0. 1 M final concentration) was added to the cells and were then
subjected to two washes with PBS and one with PBS containing 0.
5% Tween-
(PBS/Tween-20). The cells were subsequently blocked with 1 % BSA diluted in
PBS/Tween-20 for 30 minutes at room temperature. Immunohistochemical
staining for BrdU incorporation was done by incubating cells with a mouse anti-
BrdU monoclonal antibody (Boehringer Mannheim) diluted 
1 :500 in PBS/Tween-
20 containing 1 % BSA for 1 h at room temperature in a humidified chamber.
Cells were washed with PBS/Tween-20 and incubated with a biotin-conjugated
goat-anti mouse Ig secondary antibody (Vector Laboratories) diluted 
1 :250 in
PBS/Tween-20 for 1 hour at room temperature in a humidified chamber.
Afterwards , cells were washed and then incubated with a streptavidin-conjugated
substrate (Vector Laboratories) diluted 1 :200 in PBS for 30 minutes at room
temperature. The cells were washed with PBS and then incubated at room
temperature with Vectastain DAB substrate (DAB kit , Vector Laboratories) as
recommended by the manufacturer, to visualize stained nuclei. Scoring for BrdU
positive cells was done by counting the number of cells that stained positive for
BrdU incorporation per cell population. A minimum 300 total cells spread over 
or more fields was scored for each cell population from each experiment.
b. Propidium iodide (PI) staining
Cells were plated at sub-confluent densities prior to infection with the
appropriate recombinant adenoviruses. To process the samples for flow
cytometry analysis , the cells were first trypsinized , pelleted , washed with PBS
re-pelleted , and resuspended in 400 I of PBS. All centrifugations were done at
500 x g for 5 minutes at 4 C. The cells were subsequently fixed in cold ethanol
(70% final concentration). Fixed cells were washed twice with PBS and then
incubated in HCI (2N final concentration) containing pepsin (0.2 mg/ml) for 30
minutes at room temperature. Afterwards , 0. 1 M sodium tetra borate was added
and the cells were washed with PBS then blocked with PBS containing 1 % BSA.
Cells were washed three times with PBS and then resuspended in 0.5 ml PBS
containing PI and RNase A (0.5 mg/ml). Flow cytometry analysis was performed
by the UMMS Flow Cytometry Core Facility, (Worcester
, MA), and the data was
processed using the FlowJo FACS analysis program (Treestar Inc.
, CA). S-
phas cells were defined as the population of cells having greater than 2N but
less than 4N DNA content.
f'"
E. Immunohistochemical staining
Semiconfluent cultures of cells were infected with the appropriate
recombinant adenoviruses. At different times p. , cells were washed with PBS
and then fixed with formaldehyde diluted in PBS (0.37% final concentration) for 5
minutes at room temperature. The cells were washed with PBS and then
incubated in methanol (100% final concentration) for 5 minutes at room
temperature. Following several washes with PBS/Tween- , the cells were
incubated with the primary antibody diluted in PBS/Tween-20 containing 1 % BSA
for 1 hour at room temperature. The cells were washed with PBS/Tween-20 and
bound antibody was detected using a Vectastain DAB substrate kit as described
by the manufacturer. p53 protein was detected with an anti-p53 monoclonal
antibody (Ab- , Oncogene Research Products) at a 1 :500 dilution and p21
protein was detected with an anti-p21 monoclonal antibody (F-5; Santa Cruz
Biotechnology) at a 1 :250 dilution.
F. Western blot analysis
Cells were infected with the appropriate recombinant adenoviruses and
subsequently harvested at various times post infection. Whole cell extracts were
prepared by first washing the cells with cold PBS and then lysing them in 100 
III
of whole cell extract buffer (50 HEPES (pH 7. 9), 250 mM KCI , 0. 1 mM EDTA , 0.
mM EGTA , 0. 1 % Nonidet P- , 1 mM dithiothreitol , 1 mM phenylmethylsulfonyl
fluoride , 0.3 mM sodium orthovanadate , 2 mM sodium fluoride , 2 Ilg/ml
apoprotinin , 1 !lg/ml pepstatin , 2 !lg/mlleupeptin) by incubation for 30 min on ice.
To assess p21 protein , cells were washed once with cold PBS then scraped into
1 ml of RIPA buffer (PBS , 0. 1 % NP- , 1 % SDS , 0.5% sodium deoxycholate
1 % sodium vanadate , 0. 1 % PMSF , and 0. 3% aprotinin) and incubated on ice
for 1 h. Soluble proteins were isolated by centrifugation at 13 000 rpm in a
microcentrifuge , with the resulting supernatant collected and stored at -
Aliquots of cell extracts were analyzed by SDS-PAGE , and the resolved proteins
transferred to nitrocellulose membranes by electroblotting. Membranes were
incubated in blocking solution (5% non-fat milk dissolved in tris-buffered sulfate
(TBS) containing 0. 1 % Tween-20 (TBS/Tween-20)) for 1 h at room temperature.
Afterwards , membranes were incubated with primary antibody diluted in
TBS/Tween-20 containing 5% blocking solution at 4 C overnight on an orbital
shaker. HCMV IE1-72 and IE2-86 protein expression was detected with a mouse
anti-cytomegalovirus monoclonal antibody (MAB810; Chemicon International
Inc. ) at a 1 :500 dilution. p53 was detected with an anti-p53 polyclonal antibody
(Ab-7; Oncogene Research Products) at a 1 :2000 dilution , the phospho-Ser
form of p53 was detected with a polyclonal antibody specific for this modification
(#9284; Cell Signaling Technology) at a 1:1000 dilution , p21was detected with an
anti-p21 polyclonal antibody (C- 19; Santa Cruz Biotechnology) at a 1 :500
dilution , p19ARF was detected with an anti-p19ARF polyclonal antisera (NB 200-
106; Novus Biologics) used at (0.5 !lg/ml), MDM2 was detected with an anti-
MDM2 monoclonal antibody (Ab-2; Oncogene Research Products) at a 1 :500
dilution , and actin was detected with an anti-actin polyclonal antibody (1- 19;
Santa Cruz Biotechnology) at a 1 :500 dilution. The membranes were washed
with TBS/Tween-20 for three 10 min intervals at room temperature and then
incubated with secondary antibody diluted in TBS/Tween-20 containing 5%
blocking solution at room temperature for 1 h. Immunoreactive proteins were
detected by using a chemiluminescence kit (Amersham) according to the
manufacturer s recommendations.
G. Northern blot analysis
Total cellular mRNA (25 !lg/Iane) was resolved by electrophoresis under
denaturing conditions in formaldehyde-agarose gels , containing 1 % agarose , 3-
(N-morpholino) propanesulfonic acid , EDT A, and formaldehyde. After
separation , the RNA was transferred to nylon membranes by capillary blotting
overnight at room temperature. Blots were prehybridized overnight in
prehybridization buffer (10% dextran sulfate , SSPE , 1 % SDS , 0.5% non-fat milk
yeast total RNA) at 50 C. A p53 cDNA probe (SJ58 , a generous gift from
Stephen Jones) was digested with Kpnl and labeled with p. Following
prehybridization , the membrane was incubated in 5ml of prehybridization solution
containing the labeled probe at 50 C. Membranes were washed twice with 2x
SSPE for 20 min at 50 C before exposure to film or a phosphorimager screen.
H. Monitoring p53 nuclear shuttling
Heterokaryons were generated as described (168). Essentially,
subconfluent cultures of SAOS-2 cells (3 x 10 cells per 60mm plate) were co-
infected with Adp53 (MOl = 20) and either Ad1E1-72 or AdCon at the indicated
MOl. Following infection , cells were cultured in normal media at 37 C for 1.5 h.
The SAOS-2 cells werewashed twice with PBS
, then trypsinized , re-plated with
an equal number of MDMZ /p53- MEFs onto glass coverslips in 35mm plates
and incubated overnight at 37 C. Afterwards MDMZ /p53- MEFs and SAOS-
cells were washed twice with PBS and then incubated in media containing
cyclohexamide (50 !!g/ml) for 20 min at 
3rC. MDMZ /p53- MEFs and SAOS-
cells were subsequently washed twice with PBS and then incubated for 2 min in
50% polyethylene glycol (MW 3350
, SIGMA) dissolved in DMEM containing
penicillin-streptomycin to facilitate cell fusion. The treated MDMZ /p53- MEFs
and SAOS-2 cells were washed twice with PBS and incubated in media
containing cyclohexamide for 1 hr at 37 C. MDMZ
-;p53- MEFs and SAOS-
cells were then fixed with 3.7% formaldehyde in PBS for 10 min at room
temperature and permeabilized with cold 0.2% Triton X- 100 in PBS for 10 min at
To identify heterokaryons and determine the location of p53 in the
heterokaryons , cells were blocked with 10% FBS in PBS for 15 min at room
temperature prior to incubation with primary antibodies. The cells were doubly
stained with an antibody specific for human
, but not murine , Ku nuclear antigen
to distinguish human and murine nuclei
, together with an antibody that
recognizes p53. Human Ku-86 was detected using an anti-Ku86 monoclonal
antibody (sc-5280; Santa Cruz Biotechnology) diluted at 1 :200 and p53 was
detected using an anti-p53 monoclonal antibody (Ab- 1; Oncogene Research
Products) diluted at 1 :250. The p53N/C mutant was detected using an anti-p53
monoclonal antibody (1 :250 dilution) that recognized an epitope (aa 46-55) that
was not affected by the mutation to p53 (Ab-2; Oncogene Research Products). A
monoclonal antibody recognizing the two subunits of the human Ku protein
(p70/p80) (Ab-2; Oncogene Research Products) was used at a dilution of 1 :250
to identify human nuclei. After incubation with the primary antibodies , the cells
were washed three times with PBS and then incubated with an isotype-specific
fluorescein isothiocyanate (FITC)-conjugated monoclonal antibody (Southern
Biotechnology, Inc. ) diluted 1 :250 and an isotype specific rhodamine red-
(RRX)-conjugated monoclonal antibody (Southern Biotechnology, Inc. ) diluted
1 :200 , to detect p53 and human Ku- , respectively. All of the described
antibodies were diluted in 10% FBS/PBS and were incubated in a humidified
chamber for 1 hour at room temperature. Cells were washed three times with
PBS and once with distilled water. Glass coverslips containing the cells were
removed from the 35mm plates and mounted onto glass slides with Vectashield
containing 4' diamidino- phenylindole (DAPI) (H-1200 , Vector Laboratories
Inc. ) according to manufacturer s recommendations. p53 nuclear shuttling was
scored by assessing the localization of p53 protein in human 
- murine
heterokaryons using a Zeiss immunoflurorescent microscope. Results were
presented as the percentage of heterokaryons in which p53 shutted from human
to murine nuclei.
I. Luciferase assays
HEL fibroblasts were plated at subconfluent densities onto 6-well plates
and grown overnight at 37 C. Cells were co-transfected with a plasmid encoding
an IE1-72 cDNA (pcDNA3- IE1-72) or a control plasmid (pcDNA3) (2 g/well),
along with a p21-specific reporter construct , WAF- Luc (generously provided by
Karen Vousden , National Cancer Institute , Frederick , MD) (41) (1 g/well), using
Lipofectamine Plus (Invitrogen Inc. ). A renilla luciferase-expressing plasmid
pRL- TK (kindly provided by Zdenka Matijasevic , UMMS , Worcester, MA), was
also included (0. g/well) as an internal control to normalize transfection
efficiencies between samples. Transfection reactions were incubated for 5 h 
C. Afterwards , transfection media was replaced with DMEM containing 10%
FBS and cells were incubated at 37 C for 24 h. The cells were then lysed and
luciferase activity was determined using a Dual-Luciferase reporter assay system
(Promega). Results are presented as fold induction of p21 promoter activity
relative to the control plasmid transfected cells.
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CHAPTER II
Effect of HCMV IE1-72 and IE2-86 Expression on the Cell Cycle
A. Expression of HCMV IE1-72 and IE2-86 alters the cell cycle distribution of
asynchronously cycling cells
The small DNA tumor viruses
, through the ability of their viral oncoproteins
to bind to RB family members and induce E2F transactivation functions
, can alter
the distribution of cells towards S-phase (108). HCMV expresses two IE gene
products , IE1-72 and IE2- , that can interact with RB family members and
induce E2F activity (43
, 54 , 116 , 136). However, it is unclear whether the
expression of these IE proteins can alter the distribution of cells towards S-
phase. To address this issue
, asynchronously cycling REF52 cells were infected
with recombinant adenoviruses encoding cDNAs for either IE1-
72 or IE2- , and
analyzed for alteration in cell cycle distribution over time.
We utilized recombinant adenovirus technology to express the individual
HCMV IE proteins in cells. We used two recombinant adenoviruses
, Ad1E1-
and AdIE2- , in our study (3). To confirm that both recombinant adenoviruses
expressed each IE product and to determine if their expression could alter growth
control , we infected REF52 cells or MEFs with either Ad1E1-72 or AdIE2-86. The
REF52 cells line is an immortalized cell line that is permissive to infection with
recombinant adenoviruses. REF52 cells efficiently undergo growth arrest in
response to serum withdrawal and they express wild-
type p53 and RB family
. " p' '"
members. They were also the cells used to examine the effects of the
adenovirus E1A and E1 B proteins on cell growth control (87). Extracts from
REF52 cells infected with either Ad1E1-72 or Ad1E2-86 were analyzed for HCMV
IE protein expression. As shown in Figure 3. , the IE1-72-encoding and IE2-86-
encoding recombinant adenoviruses expressed the appropriate HCMV IE
proteins albeit at levels different from those observed in the HCMV- infected cells.
Cells infected with Ad1E2-86 expressed lower levels of IE2-86 protein as
compared to the HCMV- infected cells. Specifically, a higher concentration of
extract (100 ug) was needed to detect IE2-86 protein in the AdIE2-86-infected
cells. In contrast , cells infected with Ad1E1-72 expressed the IE1-72 protein at
levels exceeding those observed in HCMV- infected HELs. To maintain
consistency in our analysis of the IE proteins , 100 ug of extract was used from
the AdIE1-72- infected cells and this four-fold difference in concentration may
account for the disparity in the levels of IE1-72 protein detected in these cells
versus the HCMV- infected cells. Therefore , we utilized these recombinant
adenoviruses in our analysis.
The cell cycle distributions from IE1-72-expressing and IE2-86-expressing
cells were compared with that of the control virus (AdCon) infected cells. With
the expression of either IE1-72 or IE2- , the distribution of randomly cycling
REF52 cells was altered relative to that of the control virus-infected cells. IE1-
expression caused an increase in the percentage of REF52 cells in S-phase at
the later times post-infection (Figure 3. B; Table 3-1). Cells expressing IE1-
"'\ . .
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Figure 3. 1. IE1-72 and IE2-86 expression in REF52 cells infected with
Ad1E1-72 and AdIE2-86.
Western blot analysis of whole cell extracts from REF52 cells infected with
Ad1E1-72 or Ad1E2-86 (MOl = 250) (100 J.g/lane) or HEL cells infected with
HCMV (Towne) (MOl = 5) (25 J.g/lane). Cells were harvested at the different
hours post infection (hpi) indicated. HCMV IE proteins were detected with an
anti-cytomegalovirus monoclonal antibody specific for a common determinant
found on both IE proteins.
24 hpi 48 hpi 72 hpi
DJ ll 
MIE1.72lJG lh 
DNA content
AdCan Ad1E1-
100 100
t :
11 
'8 60
E 50
i 50
1;41
a. 30 a. 30
24 hpi 48hpi 72hpi 24hpi 48hpi 72hpi
Ad1E2-
100
G21M
E 50
1;40
a. 30
24 hpi 48 hpi 72hpi
Figure 3.
Figure 3.2. HCMV IE1-72 and IE2-86 expression disrupts cell cycle
progression in asynchronously cycling cells.
Randomly cycling REFS2 cells were infected with AdIE1- , AdIE2- , or AdCon
(MOl = SOD). Following infection , cells were fixed at the indicated times post-
infection and stained with PI. The levels of PI incorporated by the cells were
measured by flow cytometry analysis to assess cellular DNA content. (A) Plots
from REFS2 cells stained with PI depicting DNA content versus cell number; (B)
histograms summarizing flow cytometry analyses performed on REFS2 cells
which depict the percentage of cells in each phase of the cell cycle are shown in
(A). The averaged percentages from two separate experiments are shown.
Table 3. 1. Distribution of REF52 cells in S-phase following IE1-72 or IE2-
expression
Post-infection b
Recombinant 24h 48h 72h
adenovirus a
AdCon 12. 16. 17.
Ad1E1- 13. 26.4% 35.4%
Ad1E2- 38. 32. 44.4%
a Recombinant adenoviruses used at a MOl = 500
b Times at which cells were harvested and fixed. Results are shown as percent
cells in S-phase.
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exhibited almost a two-fold increase in the percentage of S-phase cells as
compared to the control virus-infected cells at 48 h (26.4% vs. 16. 3%,
respectively) and 72 h (35.4% vs. 17.5%, respectively) (Figure 3. B).
Concomitant with this increase in the percentage of S-phase cells , there was a
decrease in the percentage of cells in the G phase of the cell cycle following
IE 1-72 expression as compared to the control virus- infected cells. At both 48 
and 72 h post-infection , a lower percentage of G cells were observed in the IE1-
72-expressing cell population as compared to the control population (48 h: 49.
vs. 65.6%; 72 h: 51. 1 % vs. 69. , respectively). A similar analysis was
performed using asynchronously cycling WT MEFs. Similar to the results
observed with the REF52 cells , there was a slight increase in the percentage of
phase cells (1. fold) following IE1-72 expression as compared to the control
virus- infected cells (Figure 3. 3; Table 3-2).
IE2-86 expression had a more dramatic effect on the cell cycle distribution
of REF52 cells than IE1-72. As was observed in the cells expressing IE1- , the
distribution of the cells was altered such that there was an increase in the
percentage of cells in S-phase (Table 3- 1). By 24 h post- infection , over one-third
of the IE2-86-expressing cells appeared to be in S-phase as compared to a
smaller percentage of the control virus- infected cells (38.8% vs. 12.3%,
respectively). The same trend was observed at the later time points with IE2-
expression maintaining a two- to three-fold increase in the percentage of S-
phase cells as compared to the control virus- infected samples (Table 3- 1).
OIE1-72 .IE2-
24h 48h 72h
Hours post infection
Figure 3.3. HCMV IE1-72 and IE2-86 expression alters the normal cell cycle
distribution of p53
+/+
MEFs.
Randomly cycling p53+/+ MEFs were infected with AdIE1- , AdIE2- , or AdCon
(MOl = SOD). Following infection , cells were fixed with at the indicated times
post- infection and stained with PI. The levels of PI incorporated by the cells were
measured by flow cytometric analysis to assess cellular DNA content. Data
presented as the fold- increase in the percentage of S-phase cells relative to
control virus- infected cells.
Table 3-2. Distribution of WT MEFs in S-phase following IE1-72 or IE2-
expression
Post-infection b
Recombinant 24h 48h 72h
adenovirus a
AdCon 1S. 10.
Ad1E1- 18. 16. 18.
Ad1E2- 43. 40.4% 38.
a Recombinant adenoviruses used at a MOl = 
SOD
b Times at which cells were harvested and fixed. Results are shown as percent
cells in S-phase and represent an average of two experiments.
Moreover , IE2-86 expression caused an increase in the percentage of G /M-
phase cells as compared to the percentage observed for the control samples. By
24 h , almost one-half of the IE2-86-expressing cells (44. 1 %) were in G /M-phase
whereas a smaller proportion of the control virus- infected cells (17. 1 %) were in
/M-phase. Concomitant with the increase in the percentage of S-phase cells
IE2-86 expression caused a three to four-fold decrease in the percentage of cells
in G (Figure 3.2).
A similar outcome was observed in WT MEFs. IE2-86 expression
mediated an increase in the percentage of S-phase cells (Table 3-2). As shown
in Figure 3- , IE2-86 expression caused a two- to three-fold increase in the
percentage of S-phase cells as compared to the control virus-infected cells.
Taken together, these results indicate that HCMV IE2-86, and IE1-72 to a lesser
extent, can influence the cell cycle distribution of randomly cycling fibroblasts by
biasing the distribution towards the S- and G /M-phases of the cell cycle.
B. HCMV IE2-86 expression induces quiescent cells to enter S-phase and
delays cell cycle exit
Since HCMV IE2-86 expression altered the cell cycle distribution of
randomly cycling fibroblasts , we examined whether it could also alter the cell
cycle under more stringent measures of growth control. To approach this issue
we examined the ability of IE2-86 to (1) induce quiescent cells to enter S-phase
and (2) inhibit cells from exiting the cell cycle. To address whether IE2-86 can
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Figure 4. IE2-86 expression induces quiescent REF52 cells to proliferate
and delays cell cycle exit in REF52 cells.
(A) REF52 were rendered quiescent by culturing in the presence of 0.25% serum
and then infected with Ad1E2-86 (at the MOl indicated) or AdCon (MOl = 500).
Cells were maintained in media containing 0.25% serum following infection. (B)
Asynchronous cultures of REF52 cells were infected with Ad1E2-86 or AdCon
(MOl = 500) and then subjected to culture in media containing reduced serum
(0.25%) until harvested. Cells were pulsed with 10mM BrdU for 12 h prior to
harvesting at the indicated times post- infection. Immunohistochemical staining for
BrdU incorporation was performed using an anti-BrdU monoclonal antibody and
the number of BrdU-positive cells was scored. The average from two separate
experiments are shown in (A) and (B). Error bars represent the standard error of
the mean.
induce quiescent cells into S-phase , we expressed IE2-86 in quiescent , serum-
depleted cultures of REF52 cells and examined the cells for S-phase induction by
determining the number of cells that incorporated the proliferation marker , BrdU.
Over 90% of the control virus- infected cells underwent growth arrest following
serum withdrawal. Upon addition of serum to the culture medium , over 75% of
the cells re-entered the cell cycle. IE2-86 expression in quiescent fibroblasts
resulted in almost a 10-fold increase in the population of BrdU positive cells
relative to the control virus- infected population (Figure 3.4-A). The ability of IE2-
86 to induce S-phase in quiescent cells appeared to be dose dependent , since
the strength of the proliferative response correlated with the dose of AdIE2-86.
To determine if IE2-86 expression can delay cells from exiting the cell
cycle , we expressed IE2-86 in a population of asynchronously cycling REF52
and monitored for changes in cell cycle exit kinetics following culture in reduced
serum. Optimization experiments demonstrated that culturing REF52 cells for 36
h in reduced serum (0.25%) was sufficient to induce the majority of cells to exit
the cell cycle as measured by BrdU incorporation (data not shown). REF52 cells
were cultured in reduced serum for a minimum of 36 h after infection with the
recombinant adenoviruses and pulsed with BrdU for 12 h prior to harvest to
assess the impact of IE2-86 on cell cycle exit. By 36 h after serum withdrawal
over 90% of the control virus- infected cells became quiescent (Figure 3.4-B). As
expected , cells cultured under normal conditions (10% serum) continued to
proliferate.
Cell cycle exit in fibroblasts expressing IE2-86 was delayed as compared
to control virus- infected cells. At the highest MOl of Ad1E2-86 used , over one-
third of the population of cells (34.8%) continued to incorporate BrdU through 42
h following serum withdrawal , whereas less than 10% of control virus-infected
cells incorporating BrdU was much lower (8.2%).
To confirm that the cell cycle alterations were due to effects from IE2-
expression and not a consequence of the recombinant adenovirus approach we
employed , we transiently transfected two different plasmids containing IE2-
cDNAs into REF52 cells prior to serum withdrawal. Using this approach , we
obtained BrdU incorporation results that were similar to those obtained with the
AdIE2-86-infected cells. Specifically, 40% of the IE2-86-expressing cells stained
positive for BrdU incorporation (Table 3-3). These results suggest that IE2-
expression can delay cell cycle exit for extended periods following serum
withdrawal.
Taken together, these findings indicate that IE2-86 modulates cellular
proliferation control by inducing growth-arrested cells to enter S-phase and by
delaying cells from exiting the cell cycle.
C. Expression of IE2-86 induces proliferation and delays cell cycle exit in WT
and p53- MEFs
Viral oncoproteins from the small DNA tumor viruses such as adenovirus
SV- , and HPV have the ability to bind to p53 and inhibit its activity. Several
0''''
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Table 3-3. Delayed cell cycle exit in cells following IE2-86 expression
Post-transfection
Plasmid a 36h 48h
pHM121 42. 45.
pcDNA3 11. 17.
pcDNA3- IE2-86 b 30. 43.4%
pcDNA3 22.
a Plasm ids transfected into 
subconfluent cultures of REF52 cells at g/well.
b Percentage of cells stained positive for IE2-86 and BrdU.
c Percentage of cells stained positive for BrdU.
groups have demonstrated that HCMV IE2-86, in addition to binding to pRb , can
interact with p53 and block apoptosis. Additionally, HCMV- infected cells exhibit
elevated p53 protein levels and this may be coincident with the HCMV-mediated
growth arrest observed in these viral infections (69, 104). Because IE2-86 can
bind to p53 , we wanted to determine whether targeting of p53 by IE2-86 was
required for its ability to induce S-phase entry as well as delay growth arrest.
To address this issue, we examined the effects of IE2-86 expression in
early- passage MEFs lacking p53 (P53- and their wild-type counterparts (WT).
Although both cell types were derived from the same strain of mice (36), the WT
and p53- MEFs required different culturing conditions to yield an optimal level of
growth arrest. The WT MEFs required culturing in 0.25% serum for 48 h to
induce quiescence in these cells , and the p53- MEFs required culturing in 0. 1 %
serum for 60 h to induce arrest (data not shown). The re-addition of serum to the
culture medium stimulated both populations of quiescent MEFs to enter S-phase.
Growth-arrested MEFs were infected with varying doses of Ad1E2-86 or
:'1
control virus (MOl = 500) and then pulsed with BrdU 12 h prior to harvest to
assess DNA replication levels. Quiescent WT MEFs expressing IE2-86 were
induced to incorporate BrdU as evidenced by the increased percentage of BrdU
positive cells observed relative to control (Figure 3. A). By 48 h post-infection
over 30% of the IE2- 86-expressing p53+ MEFs (MOl = 500) incorporated BrdU
as compared to 10% of the control virus-infected cells.
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Figure 5. IE2-86 expression induces S-phase in quiescent WT and p53-
MEFs.
(A) Early passage wild-type and (B) p53- MEFs were cultured under low serum
conditions to induce growth arrest. Cells were then infected with Ad1E2-86 (at
the MOl indicated) or with AdCon and maintained under low serum conditions
after infection. Cells were pulsed with BrdU for 12 h prior to harvesting at the
indicated times post- infection. BrdU-positive cells were identified by
immunohistochemical staining using an anti-BrdU monoclonal antibody and the
number of BrdU-positive cells was scored. Results are representative of two
separate experiments for each cell type.
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IE2- 86 exhibited a similar effect when expressed in quiescent p53- MEFs
(Figure 3. B). While the culture conditions were sufficient to arrest growth for
approximately 80% of the p53- MEFs , by 48 h post-infection , IE2-86 expression
induced almost a four-fold increase in the percentage of BrdU positive p53-
MEFs (MOl = 500; 84%) as compared to the control virus- infected population
(23%). The fold induction in BrdU positive cells was similar in WT and p53-
MEFs. Therefore , the ability of IE2-86 to induce S-phase from quiescent cells is
apparently independent of p53 protein.
We next determined if p53 targeting was required for IE2-86 to delay
growth arrest following serum withdrawal. Asynchronously cycling WT and p53-
MEFs were first infected with Ad1E2-86 or AdCon and then cultured in reduced
serum to induce growth arrest. Similar to the effects seen in the REF52 cells,
IE2-86 expression delayed the ability of WT MEFs to exit the cell cycle following
culture in 0.25% serum (Figure 3. A). By 48 h post- infection , the percentage of
WT MEFs still BrdU positive following IE2-86 expression and serum withdrawal
::i
was almost three-fold higher than the percentage observed with the control virus-
infected cells (MOl = 500; 39.8% vs. 13.6%, respectively).
Delayed growth arrest by IE2-86 was also observed in cells lacking p53
(Figure 3. B). Expression of IE2-86 in the p53- MEFs resulted in a three-fold
higher percentage of BrdU positive cells relative to the control virus-infected
population at 72 h post-infection (46. 1 % vs. 15.2%, respectively). Taken
- --..
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Figure 3.6. IE2-86 expression delays cell cycle exit in WT and p53- MEFs.
(A) Early passage wild-type and (B) p53- MEFs were infected with Ad1E2-86 (at
the MOl indicated) or AdCon (MOl = SOD) and then cultured in media containing
reduced serum (0.2S%). Cells were pulsed with BrdU for 12 h prior to harvesting
at the indicated times post- infection. Cells were immunohistochemically stained
for BrdU incorporation using an anti-BrdU monoclonal antibody and the number
of BrdU-positive cells was scored. Results are representative of two separate
analyses for each cell type.
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together, these findings suggest that p53 targeting is not required by IE2-86 to
induce quiescent cells to enter S-phase or to delay cell cycle exit.
D. HCMV IE1-72 expression does not induce quiescent cells to enter S-phase
and fails to delay cell cycle exit
Since IE1-72 disrupted the normal distribution of randomly cycling cells
following the expression of IE1-72 in REF52 cells , we wanted to determine
whether IE1-72 could influence cell proliferation control in a manner similar to
IE2-86. To address whether IE1-72 could induce growth-arrested cells to enter
phase , we expressed IE1-72 in serum-starved , quiescent REF52 cells and
measured S-phase induction by BrdU incorporation. Expression of IE1-72 had
no apparent effect on quiescence since the percentage of BrdU positive cells
observed in the AdIE1-72- infected populations was comparable to the
percentage observed in the control virus- infected cells (Figure 3. 7 -A). By 48 h
post- infection and at each dose of Ad1E1-72 used , less than 10% of the IE1-72-
expressing cells were positive for BrdU. This suggests that IE1-72 cannot induce
cells to re-enter the cell cycle from quiescence.
To address whether IE1-72 could retard cell cycle exit , we expressed IE1-
72 in REF52 cells and subjected them to reduced serum conditions. Unlike IE2-
86 expression , IE1-72 expression did not delay cell cycle exit in the REF52 cells
(Figure 3. B). Analysis at earlier times post- infection and post-serum
withdrawal did not show any delay in the kinetics of cell cycle exit following IE1-
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Figure 7. IE1-72 expression fails to induce quiescent REF52 cells to enter
phase and does not delay cell cycle exit in 
REF52 cells.
(A) REFS2 cells were rendered quiescent by culturing in the presence of 0.2S%
serum and then infected with Ad1E1-72 (at the MOl indicated) or AdCon (MOl =
SOD). Following infection , cells were maintained in media containing 0.2S%
serum. Results from one representative experiment are shown. (B)
Asynchronous cultures of REFS2 cells were infected with Ad1E1-72 (at the MOl
indicated) or AdCon (MOl = SOD) and then subjected to serum withdrawal. Cells
were pulsed with BrdU for 12 h prior to harvesting. Immunohistochemical
staining for BrdU incorporation was performed using an anti-BrdU monoclonal
antibody and the number of BrdU-positive cells was scored. The average from
two separate experiments is shown. Error bars represent the standard error of
the mean.
72 expression in the REF52 cells. Taken together, these findings suggest that
IE1-72 can influence cell cycle progression in asynchronously cycling cell
populations. However, it is ineffective in altering the cell cycle under more
stringent growth conditions such as inducing quiescent cells to enter S-phase or
in delaying cell cycle exit following serum withdrawal.
E. Expression of HCMV IE1-72 induces S-phase entry and delays cell cycle exit
in the absence of p53
Although IE1-72 expression caused a modest change in the cell cycle
distribution of randomly cycling cells , it failed to induce S-phase entry in
quiescent REF52 cells and was unable to delay cell cycle exit following serum
withdrawal. This outcome was unexpected given the fact that IE1-72 has been
shown to bind to p1 07 and induce E2F activity (116). Since p53 can induce
growth arrest under certain conditions , we asked if the presence of p53 prevents
IE1-72 from inducing its proliferative effects.
To address this issue , IE1-72 was first expressed in serum-starved WT
and p53- MEFs and S-phase induction was monitored by BrdU incorporation.
Quiescent WT MEFs failed to re-enter the cell cycle following the expression of
IE1-72 as evidenced by the similar percentage of BrdU positive cells relative to
the control population (Figure 3. A). In contrast, expression of IE1-72 was able
to induce the growth-arrested p53- MEFs to enter S-phase (Figure 3. B). By 48
h post-infection , over a two-fold increase in the percentage of BrdU positive cells
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Figure 8. IE1-72 expression induces S-phase only in the absence of p53.
(A) Early passage wild-type and (B) pS3-/- MEFs were cultured under low serum
conditions to induce quiescence. Cells were then infected with Ad1E1-72 (at the
MOl indicated) or AdCon (MOl:: SOD) and maintained under low serum
conditions following infection. Cells were pulsed with BrdU for 12 h prior to
harvesting at the indicated times post- infection. BrdU-positive cells were
identified by immunohistochemical staining using an anti-BrdU monoclonal
antibody and the number of number of BrdU-positive cells was scored. Results
are representative of two separate analyses for each cell type.
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was observed in the IE1-72-expressing cells as compared to the control virus-
infected cells (MOl = SOD: 43% vs. 21 %, respectively). The ability of IE1-72 to
induce cell cycle re-entry was apparent even at the latest time point examined
(72 h) where over six-times as many IE1-72-expressing cells (MOl = SOD) scored
positive for BrdU as compared to the control virus-infected population. The re-
addition of serum had a nominal effect on the p53- MEFs , which may be
attributed to the stringent conditions required to render these cells quiescent.
To address whether pS3 hinders IE1-72 from delaying cell cycle exit , IE1-
72 was expressed in WT and p53- MEFs prior to serum withdrawal. IE1-
expression did not perturb the WT MEFs from exiting the cell cycle following
serum withdrawal (Figure 3. A). At each of the time points analyzed , the
percentage of BrdU positive cells observed in each of the IE1-72-expressing cell
populations was less than or equal to the percentage observed in the control
virus- infected population. These results are consistent with those obtained by
expressing IE1-72 in REFS2 cells suggesting that IE1-72 has no effect on
delaying cell cycle exit following serum withdrawal in cells containing pS3.
IE1- 72 had a different effect in the p53- MEFs. Expression of IE1-
delayed cell cycle exit in the p53- MEFs following culture in 0. 1 % serum (Figure
B). After 72 h , over one-third of the IE1-72-expressing cells remained cycling
as compared to a smaller percentage of the control virus- infected cells (MOl =
SOD: 36% vs. 16.S%, respectively). The ability of IE1-72 to delay cell cycle exit
was apparent even at the latest time point examined (96 h). Taken together
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Figure 3.9. IE1-72 expression delays cell cycle exit in the absence of p53.
(A) Early passage wild-type and (B) p53-/- MEFs were infected with Ad1E1-72 (at
the MOl indicated) or AdCon (MOl = 500) and then serum starved. Cells were
pulsed with BrdU for 12 h prior to harvesting at the indicated times post- infection.
Cells were immunohistochemically stained for BrdU incorporation using an anti-
BrdU monoclonal antibody and the number of BrdU-positive cells was scored.
Results are representative of two separate analyses for each cell type.
these findings suggest that p53 can mask the proliferative capacity of IE1-72. In
the absence of p53 , IE1-72 expression can induce quiescent cells to enter S-
phase and can delay cell cycle exit following serum withdrawal.
F. Expression of either HCMV IE1-72 or IE2-86 induces p53 protein
accumulation
We have shown that both IE1-72 and IE2-86 can modulate the cell cycle.
Expression of the IE2-86 protein has a more prominent effect on proliferation
control. It induces S-phase and delays cell cycle exit under all of the growth
conditions that we tested. Similarly, we found that IE1-72 has the capacity to
exert comparable effects on proliferation control , but only in the absence of p53.
Given that expression of the small DNA tumor virus oncoproteins can lead to the
accumulation of p53 protein (108), and that under certain circumstances p53
accumulation leads to growth arrest at G (153), we determined whether
expression of the IE proteins affected p53 protein levels. Although other groups
have previously demonstrated that expression of HCMV IE2-86 causes an
elevation in the levels in p53 protein in human cells (103, 140), we wanted to
verify whether the expression of IE1-72 and IE2-86 induced p53 protein in the
rodent fibroblasts used in our analysis.
To address this issue , we infected asynchronously cycling REF52 cells
with AdIE1- , AdIE2- , or AdCon , and then immunohistochemically stained for
p53 protein. Infection with AdCon did not have an effect on p53 levels in the
- -
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REF52 cells. In contrast, expression of either IE1-72 or IE2-86 resulted in
increased p53 protein accumulation in cells (Figure 3. 10). In both instances , the
accumulation of p53 protein was localized primarily to the nucleus. This extends
the earlier observation demonstrating that the IE2-86 induces p53 protein and
causes p53 to become nuclear localized (103 , 140). A similar effect was
observed in the IE1-72-expressing cells. As a positive control , we infected cells
with AdE2F1 , a recombinant adenovirus that expresses E2F1 , a factor that
members of our group have previously shown to induce p53 protein
accumulation in rodent fibroblasts (82). As expected , expression of E2F1 caused
p53 protein to accumulate in most of the cells.
To further analyze the effect of IE1-72 on p53 protein , we examined p53
levels in IE1-72-expressing WT MEFs by Western blot analysis. As compared to I'.
II 
the levels of p53 detected in the control virus-expressing WT MEFs , the cells
expressing IE1-72 exhibited almost a two- to three fold increase in the levels of
liil!
III,
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lirlip53 that was apparent as early as 24 h post- infection (Figure 3. 11). This
outcome is consistent with the result observed in Figure 3. 10 and suggests that
IE1-72 induces p53 protein accumulation.
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Figure 3.10. IE1-72 and IE2-86 expression promotes p53 accumulation in
REF52 cells.
Near-confluent cultures of REFS2 cells were infected with AdIE1- , AdIE2-
or AdCon (MOl SOD) and cultured in normal media following infection. Cells were
infected with AdE2F1 served as a positive control. At 24 h post-infection , cells
were harvested , fixed with formaldehyde , and immunohistochemically stained for
pS3 using an anti-pS3 monoclonal antibody.
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Figure 3. 11. IE1-72 expression induces p53 protein in WT MEFs.
Western blot analysis was performed on whole cell extracts from WT MEFs
infected with either Ad1E1-72 or control virus. Cells were harvested at the
indicated times post- infection. An extract from Mdm2- /p53-/- MEFs was
included as a negative control in our analysis. Endogenous p53 protein was
detected using a commercially available anti-p53 polyclonal antibody. Actin
levels were probed as a loading control.
, ,
G. Discussion
We initially set out to characterize the effects of HCMV IE1-72 and IE2-
on the cell cycle by modeling our analysis of the HCMV IE proteins to that of the
studies performed on the human adenovirus E1A and E1 B proteins due to the
fact that these proteins can perturb the cell cycle by targeting members of the RB
family of proteins and p53. The results presented in this chapter suggest that
expression of the HCMV IE proteins can modulate the cell cycle, presumably to
promote an environment that is conducive for viral replication. Specifically, we
found that expression of IE2-86 can drive cells out of quiescence and into S-
phase as well as delay cells from exiting the cell cycle into G . We also observed
that IE1-72 could mediate effects similar to those of IE2- , but only in cells
lacking p53. Moreover, we found that expression of IE1-72 or IE2-86 induces
p53 protein accumulation in rodent fibroblasts.
Although rodent fibroblasts are not permissive to HCMV replication , we
utilized these cells in our analysis because these were the cell types used in the
studies of the effects of adenovirus E1A and E1 B on the cell cycle (87). The rat
fibroblast cell line (REF52) expresses wild-type p53 and RB family members and
responds very well to serum withdrawal by undergoing growth arrest. This
particular characteristic was vital to our study and enabled us to examine closely
the effects of IE1-72 and IE2-86 on the cell cycle under varying levels of growth
stringency. Moreover, the use of the REF52 cells in our initial experiments
allowed us to establish the conditions necessary for our subsequent studies in
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wild-type and p53-deficient mouse fibroblasts. By incorporating fibroblasts from
wild-type and p53-null mouse embryos in our study, we could assess the effect of
IE1-72 and IE2-86 on the cell cycle in the presence or absence of p53 in cells
that are genetically identical without having to worry about complications , such as
genetic variability, arising from the use of transformed cell lines that lack or
contain mutated forms of p53.
Several reports indicate that HCMV induces certain cells such as human
fibroblasts to undergo growth arrest following infection (19 , 35, 69, 88). While
our findings for IE1-72 and IE2-86 are not consistent with these observations
they are consistent with other reports showing that HCMV infection promotes cell
cycle progression in other cell types. Specifically, these studies show that HCMV
induces DNA synthesis and promotes events that are characteristic of early S-
phase such as pRb hyperphosphorylation , increased cyclin E and Cdk2 protein
expression , and activation of cyclin E-cdk2 activity, (20, 69). Thus, these findings
suggest that by influencing activities that are associated with S-phase entry,
HCMV has the capacity to induce an S-phase-like environment in infected cells.
Moreover, HCMV infection induces S-phase in other cell types including
endothelial cells, smooth muscle cells, and monocytes (132 , 175), it appears that
the virus mediates divergent effects on the cell cycle.
The ability of HCMV to differentially affect the cell cycle may be attributed
in part to IE1-72 and IE2- 86. Because both IE proteins target certain RB family
members , one would expect expression of IE1-72 or IE2-86 to influence cell
- - -- - - - - -- - - -
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proliferation in a positive manner. To properly assess this, we employed a
strategy where we tested the ability of the IE proteins to influence cellular
proliferation under varying levels of growth stringency. Specifically, we examined
the effect of IE protein expression on cycling cells (low stringency), cells
undergoing growth arrest (medium stringency), and quiescent cells (high
stringency). We found that IE2-86 expression alters the distribution of randomly
cycling cells towards S-phase and delays cells from exiting the cell cycle. These
results suggest that IE2-86 exerts a growth-promoting effect on the cell cycle in
all of the growth stringency conditions tested and implies that IE2-86 can
modulate the cell cycle to generate an S-phase- like environment in cells.
IE2-86 exerts a similar effect on the cell cycle under high levels of growth
stringency. In particular, we found that IE2-86 expression induces quiescent
cells to enter S-phase. This observation is consistent with results from other
contemporary studies showing that IE2-86 induces entry into early S-phase (105,
160). Given that IE2-86 binding to pRb is sufficient to relieve the pRb-mediated
repression of E2F-responsive promoters (43 54), it is not surprising that IE2-
expression can drive cells out of G /G1-phase and into S-phase. Moreover , IE2-
86 induces cyclin E expression and can modulate other factors associated with
phase entry including E2F1 , thymidine kinase , and DNA polymerase a (17
136). Taken together, these findings suggest that IE2-86 can promote a cellular
environment that is conducive to proliferation.
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We also examined IE1-72 protein to determine if it could influence cell
proliferation control. Analogous to IE2- , there are several lines of evidence
that suggest a link between IE1-72 and overcoming cell cycle control. IE1-
binds to p107 and can overcome the p107-mediated repression of an E2F-
responsive promoter (116). Additionally, IE1-72 can phosphorylate the pocket
proteins, p107 and p130 , as well as several members of the E2F family of
transcription factors in vitro (111). Although the significance of these events to
the cell cycle is not known , the IE1-72- induced modification of p107 and p130
may influence their ability to repress E2F. Finally, IE1-72 can activate
expression from the DHFR and DNA polymerase a promoters (59 , 94), both of
which are induced during the transition from G to S-phase and are factors
required for cellular DNA synthesis. Based on these lines of evidence , we
assumed that IE1-72 expression could mediate a proliferative phenotype similar
to the one observed for IE2-86-expressing cells. Contrary to the observations for
the IE2-86-expressing cells , we found that IE1-72 expression does not alter the
cell cycle in normal rodent or murine fibroblasts. However , in the absence of
p53, IE1-72 expression was sufficient to induce S-phase entry and delay cell
cycle exit in MEFs. Thus , these observations indicate that under certain
conditions , IE1-72 has the capacity to alter cell cycle control.
The inability of IE1-72 to modulate the cell cycle in the presence of p53
implies a role for p53 in negatively influencing the effect of IE1-72 on the cell
cycle. This notion is reinforced by our observations of nuclear p53 accumulation
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and increased p53 levels following IE1-72 expression. Given that increases in
p53 protein correlate with an increase in p53 protein activity (153), the observed
elevation in nuclear p53 protein levels following IE1-72 expression coupled with
the lack of a p53- inactivating function ascribed to IE1-72 may account for the
inability of IE 1-72 to modulate the cell cycle in wild-type fibroblasts. Therefore, it
is feasible that the presence of increased p53 protein levels negates the
proliferative capacity of IE1-72 through an undefined mechanism.
We also observed nuclear p53 protein accumulation in cells following IE2-
86 expression. This observation is consistent with the ability of IE2-86 to
stabilize p53 protein levels in cells (44). However, in contrast to IE1- , IE2-
can interact with p53 and block its transactivation function (140 , 152). In addition
to p53 , IE2-86 interacts with p21 and abrogates its activity (132). Thus , the
capacity of IE2-86 to promote S-phase entry and delay cell cycle exit despite
inducing p53 protein in wild-type cells is likely attributed to its ability to inhibit p53
and p21 function.
The results presented in this chapter indicate that the HCMV proteins IE1-
72 and IE2-86 are capable of altering cell cycle control. Additional evidence
demonstrating the proliferative capacity of the IE proteins stems from a study
showing that HCMV infection increases rat SMC proliferation (175). Although
non-permissive for HCMV replication , IE1-72 and IE2-86 expression still occurs
in the rat SMCs. Taken together , these findings support the idea that HCMV
through the expression of the IE proteins , positively influences cell proliferation
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and provides at least two potential mechanisms by which HCMV can modulate
the cell cycle in vivo. In one instance , HCMV infection of quiescent cells may
induce these cells to re-enter the cell cycle and promote entry into S-phase.
Another possibility is that following HCMV infection , cycling cells continue to
progress through the cell cycle due to their inability to growth arrest.
CHAPTER IV
Mechanisms by which HCMV IE1-72 induces p53 protein accumulation
A. HCMV IE 1- 72 does not affect p53 RNA levels
In the previous chapter, we observed that expression of either IE1-72 or
IE2-86 induces p53 protein accumulation in rodent fibroblasts. This finding is
consistent with other reports demonstrating that HCMV induces p53 protein (69
104). The ability of HCMV to alter p53 levels may be attributed to the IE proteins.
IE2-86 binds p53 and can transactivate the p53 promoter (103 140). Unlike IE2-
, IE1- 72 cannot bind to p53 and has no effect on the p53 promoter (103).
Because IE1-72 expression can alter p53 protein levels in cells , we wanted to
elucidate the mechanism(s) by which IE1-72 induces p53 protein accumulation.
Given that IE1-72 can function as a transcriptional co-activator of numerous
cellular, as well as , viral promoters , we asked if IE1-72 induces p53 protein levels
by enhancing its transcription. Specifically, we looked for changes in p53 mRNA
levels in REF52 cells expressing IE1-72. We found that IE1-72 expression did
not affect p53 mRNA levels in cells (Figure 4. 1). This outcome is consistent with
the results from transient p53 promoter/reporter assays showing that IE1-72 fails
to activate expression from a p53- promoter reporter construct (103). We
included mRNA extracts from both mock- and AdE2F1- infected cells as a
negative control since E2F1 does not activate expression from the p53 promoter
(153). As expected , there was no change in p53 mRNA levels
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Figure 4. 1. IE1-72 expression does not affect p53 mRNA levels.
Northern blot analysis was performed on mRNA extracts from REFS2 cells
infected with either Ad1E1-72 or a control virus (AdCon) (MOl = 2S0). Extracts
from mock- infected and AdE2F1- infected cells (MOl = SOD) were included as
controls. mRNA extracts were harvested at 48 and 72 h post- infection. A p53
cDNA probe was used to detect p53 mRNA (expected size = 2.8 kb).
observed between the AdE2F1- infected cells and mock-infected cells. The
inability of IE1- 72 to affect p53 expression suggests that IE1-72 modulates p53
protein levels through a post-transcriptional mechanism.
B. Expression of HCMV IE1-72 induces p19ARF protein
Because IE1-72 did not affect the expression of p53, we considered the
other ways by which IE1-72 could alter p53 protein levels in cells. Normally, p53
has a very short half- life in cells (t /2 =20 min). This is attributed primarily to the
MDM2 protein , which promotes the degradation of p53 by the proteosome (45
, 58 , 63). Functioning upstream of MDM2 is p1 gARF , a nucleolar protein that
facilitates the stabilization of p53 protein through its ability to bind MDM2 and
inhibit its activity (75 , 117 , 158). Consequently, increases in p1 gARF protein
enhance the stability of p53 thereby augmenting the levels of p53 protein in cells
(117 170). We examined p19ARF protein levels in REF52 cells expressing IE1-
72 via Western blot analysis and found that compared to control virus- infected
cells , IE1-72 expression caused almost a three-fold increase in p1gARF protein
(Figure 4.2). Therefore , it appears that IE1-72 could modulate p53 protein levels
by increasing the levels of p19ARF protein in cells.
C. HCMV IE1-72 expression induces p53 protein levels in the absence of p1gARF
Given that the stabilization of p53 protein can occur through other
mechanisms besides the p19ARF/MDM2 pathway, we measured p53 protein
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Figure 4.2. IE1-72 expression induces p19ARF protein.
Western blot analysis was performed on whole cell extracts from REF52 cells
infected with either Ad1E1-72 or a control virus (Ad gal) (MOl = 250). Cells were
harvested at the indicated times p. i. Extracts were probed for endogenous
p19ARF protein using an anti-p19ARF polyclonal antibody. Actin levels were probed
as a loading control.
levels in p19fJ.RF-I- MEFs to determine if p19ARF is necessary for p53 induction
following IE1-72 expression. As shown in Figure 4. , low levels of p53 protein
were detected in the uninfected and control virus- infected cell populations
demonstrating that infection with the recombinant adenoviruses does not alter
p53 levels. Increased levels of p53 protein were observed in the IE1-72-
expressing cells in which IE1-72 expression caused up to a two-fold increase in
p53 protein levels as compared to the control virus- infected cells. Because
others have shown that exposure to UV induces p53 protein MEFs (8 , 9), we UV-
irradiated p1gARF-I- MEFs and included the extract as a positive control. An
abundant amount of p53 protein accumulated in p1gARF-I- MEFs at 24 h following
a 60 J/mm dose of UV radiation. Therefore , these findings suggest that the
ability of IE1-72 to modulate p53 protein levels is not solely dependent on p1gARF
and raises the possibility that IE1-72 acts through additional mechanism to alter
p53 protein levels.
D. HCMV IE1-72 expression increases the levels of phospho-Ser p53 in cells
We found that IE1-72 can induce p53 protein in the presence or absence
of p19ARF , implying that an additional mechanism exists by which IE1-72 affects
p53 protein levels. In addition to the p19ARF/MDM2 pathway, stabilization of p53
proteinJevels can occur through the covalent modification of p53 (118). A well-
studied model of this process is the up-regulation of p53 protein levels following
exposure to either UV or ionizing radiation. DNA damage induces p53
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Figure 3. IE1-72 induces p53 protein in the absence of p19ARF
Western blot analysis was performed on whole cell extracts from pHfRF-I- MEFs
infected with either Ad1E1-72 or control virus (MOl = 250). Cells were harvested
at the indicated times p. i. Extracts from uninfected p1 gARF-I- MEFs and p53-
MEFS were included as negative controls in our analysis. An extract from UV-
irradiated p19ARF I- MEFs infected with AdCon was included as a positive control.
Endogenous p53 protein was detected using a commercially available anti-p53
polyclonal antibody. Actin levels were probed as a loading control.
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phosphorylation at certain N- and C-terminal residues and as a result of these
modifications the protein is stabilized (153). Phosphorylation at the Ser 8 residue
of mouse p53 (Ser15 on human p53) is a common event in response to DNA
damage and enhances p53 stability (118). To test whether IE1-72 induces this
modified form of p53 , we expressed IE1-72 in WT MEFs and monitored the
levels of phospho-Ser p53 with a commercial antibody specific for this modified
form of p53. As shown in Figure 4.4- , an almost two-fold higher level of
phospho-Ser p53 protein was observed in extracts from wild-type cells
expressing IE1-72 as compared to extracts from the control virus- infected cells.
The levels of phospho-Ser p53 following IE1-72 expression remained elevated
throughout the time course of the experiment. We performed a similar
experiment using p19/J.RF-I- MEFs to determine if p19ARF was required by IE1-72 to
increase the levels of the phospho-Ser18 form of p53. A greater increase in the
levels of phospho-Ser p53 was observed in the p1fI t- MEFs following IE1-
expression (over twenty-fold as compared to the levels observed in the control
virus- infected population), suggesting that the p1 gA /MDM2 pathway was not
required for this modification to p53 (Figure 4.4-B). Thus , it appears that in
addition to affecting the p19ARF/MDM2 pathway, IE1-72 may also influence p53
protein by inducing the phosphorylation of p53 at Ser
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Figure 4.4. IE1-72 expression increases phospho-Ser p53 levels
Western blot analysis was performed on whole cell extracts from (A) WT MEFs
and (B) p1gARF-I- MEFs infected with either Ad1E1-72 or a control virus (Ad gal)
(MOl = 250). Cells were harvested at the indicated times p. i. Phosphorylated
p53 at Ser 8 was detected using a polyclonal antibody specific for this modified
form of p53. Actin levels were detected as a loading control.
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E. Phosphorylation of p53 at Ser 8 following HCMV IE1-72 expression requires
ATM
We found that IE1-72 expression in rodentfibroblasts induces the
phosphorylation of p53 at Ser , which corresponds to Ser 5 on human p53.
Several kinases have been shown to phosphorylate p53 at Ser 8 (or Ser
following DNA damage including the product of the ataxia telangiectasia mutated
(A TM) gene , the A TM-Rad3-related protein (A TR), DNA protein kinase (DNA-
PK), and the checkpoint kinase-2 protein (CHK2) (118). These kinases have
been shown to be sensitive to caffeine (14 , 125). Therefore , we determined if the
levels of phospho-Ser p53 induced by IE1-72 are affected by caffeine by
culturing IE1-72-expressing WT MEFs in media containing increasing doses of
caffeine. Consistent with the results observed from our earlier experiments using
WT MEFs , in the absence of caffeine , IE1-72-expressing cells displayed a higher
level of phospho-Ser p53 relative to that seen in the control-virus infected cells
(Figure 4.5) as shown previously (Figure 4.4-A). In the presence of caffeine , a
dose-dependent decrease in the levels of phospho-Ser p53 was observed in
IE1-72-expressing cells. Specifically, the reduction in the levels of phospho-
Ser p53 observed following caffeine treatment was comparable to the decrease
in phospho-Ser p53 reported by others utilizing caffeine at similar doses to
assess ATM and CHK2 activity (125). These results imply that a caffeine
sensitive kinase phosphorylates p53 at Ser 8 following IE1-72 expression.
However, it is unclear whether caffeine treatment also mediated an effect on the
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Figure 4.5. Phosphorylation of p53 at Ser following IE1-72 expression is
sensitive to caffeine treatment
Western blot analysis was performed on whole cell extracts from early passage
WT MEFs infected with either Ad1E1-72 or a control virus (AdCon) (MOl = 250).
Cells were cultured in the presence of increasing doses of caffeine for 6 h prior to
harvesting at 24 h p. i. Phospho-Ser18 form of p53 was detected using a
monoclonal antibody specific for this modification. Actin levels were probed as a
loading control.
levels of endogenous p53 protein in the IE1-72-expressing cells since we did not
examine total p53 protein levels in these cells.
Because we find that treatment with caffeine abrogates phosphorylation of
p53 on Ser and that a caffeine sensitive kinase is required for this modification
we set out to identify the cellular kinase(s) responsible for phosphorylating p53 at
Ser 5 following IE1-72 expression. ATM is a primary signal transducer that 
activated following DNA damage or double strand breaks (39). Recent studies
have shown that the rapid phosphorylation of human p53 after ionizing radiation-
induced damage requires ATM (10 107). To determine if ATM is required for
p53 phosphorylation at Ser 8 following IE1-72 expression , we utilized dermal
fibroblasts from ataxia telangiectasia patients (AT) in our analysis. AT patients
have an inactivated A TM gene and as a result , fail to execute many of the
cellular responses to DNA damage including phosphorylating p53 at Ser , due to
their inability to express a functional A TM protein. The levels of p53
phosphorylation following IE1-72 expression in AT fibroblasts were compared
with the levels observed in age-matched , normal human dermal fibroblasts (WT)
expressing IE1-72. IE1-72 expression in the WT fibroblasts resulted in almost a
five-fold increase in the level of phospho-Ser p53 as compared to the level
observed in the control virus- infected WT fibroblasts (Figure 4.6). Concomitant
with this observation , the level of total p53 was slightly elevated (1. fold) in the
IE1-72-expressing WT fibroblasts as compared to the control virus- infected
samples. These results are consistent with the results observed in Figures 3.
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Figure 4.6. Phosphorylation of p53 at Ser15 following IE1-72 expression
requires ATM
Western blot analysis was performed on dermal fibroblasts isolated from a
patient with ataxia telangiectasia (AT) or an age and gender-matched normal
donor (WT) infected with either Ad1E1-72 or a control virus (MOl = 250). Whole
cell extracts were harvested at 24 h p. i. Phospho-Ser15 forms of p53 were
detected using a polyclonal antibody specific for this p53 modification. p53
protein was detected using an anti-p53 polyclonal antibody. Actin levels were
probed as a loading control.
and 4.4 where IE1-72 expression causes an increase in endogenous p531evels
and phospho-Ser 53 respectively, in p53+/+ MEFs. Furthermore , the disparity
seen between the change in phospho-Ser p53 and total p53 levels following
IE1-72 expression (4. fold vs. 1. fold , respectively) implies that the
accumulation of phospho-Ser p53 observed in the WT fibroblasts does not
occur as a result of an increase in total p53 protein.
IE1-72 expression in the AT fibroblasts yielded different results. The level
of phospho-Ser p53 detected in the AT fibroblasts expressing IE1-72 was
three-fold lower than that detected in the AdIE1-72- infected WT fibroblasts.
Additionally, similar levels of phospho-Ser p53 were observed in the AT
fibroblasts infected with Ad1E1-72 or AdCon (Figure 4.6). Moreover IE1-
expression had no effect on p53 levels in the AT fibroblasts since the level of
total p53 detected in the AdIE1-72- infected fibroblasts was comparable to that
observed in the control virus- infected fibroblasts. Taken together, these findings
demonstrate that in the absence of ATM , IE1-72 fails to alter the levels of
phospho-Ser p53 as well as total p53.
F. HCMV IE1-72 expression promotes the nuclear retention of p53
We previously found that p53 localizes to the nuclei of IE1-72-expressing
cells (Chapter III). One possible explanation for this observation is that IE1-
inhibits the ability of p53 to shuttle in and out of nucleus from the cytoplasm. The
p53 protein contains at least three nuclear localization sequences and one
nuclear export sequence (147 , 155). These nuclear localization sequences are
sufficient to mediate the shuttling of p53 from the cytoplasm into the nucleus and
the nuclear export sequence can mediate the export of p53 from the nucleus.
MDM2 can also promote export of p53 out of the nucleus (124 , 150).
Recently, it was shown that phosphorylation of human p53 at the Ser
residue enhances p53 nuclear accumulation by abrogating the ability of p53 to
shutte between the nucleus and the cytoplasm (169). Since IE1-72 expression
induced the levels of phospho-Ser p53 , we asked if IE1-72 expression also
interferes with p53 shuttling. To test this possibility, we generated heterokaryons
in which p53-deficient SAOS-2 cells were infected with a recombinant adenovirus
encoding a human p53 eDNA , Adp53 , and in some instances , AdIE1-72. The
infected SAOS-2 cells were then fused with MDMZ /p53- MEFs. The resulting
heterokaryons were identified via staining for human Ku-86 and the location of
p53 assessed by indirect immunofluorescence (Figure 4. A). Shuttling of p53 to
the mouse nucleus was observed in the majority of heterokaryons formed from
SAOS-2 cells expressing p53 alone (Figure 4. B). Co-infection with a
recombinant adenovirus encoding an MDM2 eDNA, AdMDM2 , slightly diminished
p53 nuclear shuttling within the heterokaryons whereas cells co-infected with
both AdMDM2 and Adp19ARF exhibited decreased p53 nuclear shuttling as
reported previously (data not shown) (169).
In the presence of IE1- , p53 nuclear shuttling occurred in only 25% of
the heterokaryons formed from SAOS-2 cells co-expressing p53 and IE1-
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Figure 4.7. IE1-72 expression induces p53 nuclear retention
(A) SAOS-2 cells were co- infected with Adp53 (MOl = 20) and either Ad1E1-72 or
a control virus. Two hours after infection , cells were re- plated with MDMZ -;p53-
MEFs and cultured overnight at 37 C. The cells were then fused together by
treatment with PEG and de novo protein synthesis was inhibited with
cyclohexamide. Cells were fixed 1 h after fusing. Immunofluorescent detection
of human Ku-86 (red) and p53 (green) was performed to identify the human
mouse heterokaryons and the location of p53. (B-C) Human-mouse
heterokaryons (N=20) were counted from each of the experiments. (D) SAOS-
cells were infected with Adp53N/C (MOl = 20) and either Ad1E1-72 or AdCon and
the same procedure as described in (A) was used to assess p53 shuttling. The
appearance of p53 protein in the mouse (Ku-86-negative) nuclei was scored as
positive for shuttling. The averaged results from two separate experiments are
shown in (B). The averaged results from three separate experiments and the
standard deviation derived from the mean are depicted in (C and D). Numbers in
parentheses indicate MOl of virus used.
(MOl:: 100) as compared to heterokaryons containing only p53 (55%) (Figure
B). Infection of SAOS-2 cells with a higher dose of Ad1E1-72 (MOl:: 250)
prior to fusion resulted in a more dramatic decrease in p53 nuclear shutting as
compared to heterokaryons that contained only transduced p53 (5% vs. 55%,
respectively). Co- infection with a control recombinant adenovirus, AdCon , did
not impede the ability of p53 to shuttle from human nuclei to mouse nuclei in
heterokaryons because p53 nuclear shuttling occurred in an equal percentage of
C). This finding demonstrates that the increased vector load did not affect
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heterokaryons formed from SAOS-2 cells infected with only Adp53 (Figure 4.
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We substituted Adp53 with Adp53N/C, a recombinant adenovirus that
encodes a mutant form of p53 whose serine phosphorylation sites have been
modified to alanine residues (8), to determine whether p53 phosphorylation is
required by IE1-72 to disrupt p53 nuclear shuttling. As shown in Figure 4.
IE1-72 expression had no effect on p53 nuclear shutting since p53 shutting was
detected in an equal percentage of heterokaryons formed from SAOS-2 cells
infected with Adp53N/C either alone or in combination with AdCon. Therefore,
the nuclear accumulation of p53 following IE1-72 expression appears to be due
at least in part , to the ability of IE1-72 to abrogate p53 nuclear shuttling and that
p53 phosphorylation plays a critical role in this process.
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G. Discussion
In the previous chapter, we reported that IE1-72 promotes nuclear p53
accumulation in cells. Because increases in p53 protein correlate with an
increase in p53 activity (153), this IE1-72-mediated accumulation of p53likely
contributes to the inability of IE1-72 to induce S-phase and delay cell cycle exit in
p53-expressing cells. However, the mechanism of p53 protein induction by IE1-
72 was unclear. In this chapter, we present evidence that IE1-72 may induce
p53 protein accumulation through two possible mechanisms: by inducing (1)
p19ARF protein and (2) the phosphorylation of p53 at Ser . Additionally, we
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demonstrate that p53 phosphorylation on Ser following IE1-72 expression
Accumulation of p53 protein occurs in response to different types of stress
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requires ATM. Finally, we show that IE1-72 promotes p53 nuclear accumulation
by abrogating p53 nuclear shuttling.
including DNA damage , hypoxia , and oncogene expression (153). As a
consequence of this induction , p53 activity is enhanced leading to either growth
arrest or apoptosis. To counter these p53-mediated effects, the small DNA
tumor viruses express viral oncoproteins that inactivate p53 (108). By overriding
the functions of RB proteins and blocking p53 activity, the small DNA tumor
viruses generate an environment that is conducive to the replication of their viral
DNA.
Analogous to the small DNA tumor virus oncoproteins , the HCMV IE
proteins, IE1-72 and IE2- , can interact with members of the RB family to
alleviate the RB-mediated repression of E2F-responsive promoters (43 , 116).
Additionally, IE2-86 interacts with p53 and can block p53 transactivation function
(140 152). As we have demonstrated in the previous chapter , IE2-86 expression
is sufficient to induce quiescent cells to enter S-phase and delay exit from the cell
cycle. Since IE1-72 also inactivates an RB family member, one might expect
IE1-72 to mediate a similar effect as IE2-86. In contrast to this notion, IE1-
expression is not sufficient to induce S-phase and delay cell cycle exit in cells
containing wild-type p53. IE1-72 causes p53 protein accumulation , but does not
block its activity. Thus , it appears that the inability of IE1-72 to induce
proliferation in the presence of p53 is likely attributed to IE1-72 induction of p53
protein and its incapacity to inhibit p53 function.
We demonstrated by immunohistochemical staining and immunoblot
analysis that IE1-72 expression modualates p53 protein levels. However, the
molecular mechanism by which IE1-72 induces p53 protein was not known.
Given that IE1-72 can co-activate numerous cellular promoters (59 , 94), we
examined its effect on p53 expression. We found that IE1- 72 does not affect p53
mRNA levels. Our observation that IE1-72 does not alter p53 at the
transcriptional level is consistent with an earlier report showing that IE1-72 fails
to transactivate a transfected p53 promoter-reporter construct (103), and
suggests that IE1-72 alters p53 proteins through a more indirect mechanism.
There is an existing precedent that p53 stability can be regulated at the
posttranslationallevel. Normally, p53 exists at low levels in cells due to a short
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half- life. The rapid turnover of p53 is attributed to MDM2 , which facilitates p53
degradation by the proteosome (45, 46 , 58 , 63). The p1 gARF nucleolar protein
can bind to MDM2 and inhibit its activity, thereby stabilizing p53 protein levels
(75 , 117 , 158 , 170). Numerous studies have shown that oncogenes such as E2F
can stabilize p53 protein levels by inducing p1gARF (12 120). Thep1gARF
promoter contains E2F-responsive elements and p1gARF expression is activated
by E2F (33). Additionally, both the adenovirus E1A protein and polyomavirus
large T antigen require p19ARF to induce p53 protein (31 , 85). Therefore, it
appears that p19ARF serves as a key regulator of p53 protein in cells.
In light of the fact that p19ARF governs p53 stability, we hypothesized that
Ii 
IE1-72 stabilizes p53 protein through p19ARF. Although we did not assess the
effect of IE1-72 on p1gARF transcription , we examined p19
ARF protein levels in
.1 
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cells expressing IE1-72. We found that IE1-72 expression induces p1gARF
protein. This observation is consistent with the predicted outcome one might
expect given that IE1-72 can relieve the p107-mediated repression of E2F-
: !I)
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responsive promoters in cells (116). However , in contrast to the E1A protein and
middle T antigen , our results demonstrate that IE1-72 can also modulate p53
protein levels in cells lacking p19ARF . This suggests that IE1-72 can function in a
p19ARF independent manner to induce p53 and implies that IE1-72 operates
through a separate pathway to modulate p53 levels.
It is well accepted that the covalent modification of p53 contributes to its
stabilization and activation. In particular, the phosphorylation of p53 at certain N-
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terminal serine residues significantly enhances p53 protein stability by disrupting
the interaction between p53 and MDM2 (118). Studies of the cellular responses
to ultraviolet or ionizing radiation indicate that phosphorylation of Ser15 on p53
(Ser on mouse p53) is a major event following DNA damage. This modification
leads to the accumulation of p53 protein in the nuclei of cells by hindering p53
nuclear shutting and likely enhances p53 protein stabilization by reducing the
levels of cytoplasmic p53 protein (10 , 22 107 169). In addition to ultraviolet or
ionizing radiation , recent studies have shown that other events can induce the
phosphorylation of p53 at this particular residue. For instance , targeting of the
pRb protein by the polyomavirus large T antigen is required to induce p53
phosphorylation on Ser18 in polyomavirus- infected rodent fibroblasts (34).
:rl
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Moreover, our laboratory and others have shown that the expression of certain
I',j
E2F family members induces the phosphorylation of p53 at Ser (33 , 120).
:!I
These findings imply a link between the E2F proteins and p53 phosphorylation at
Ser18 (Ser15 on human p53).
, 'J
Given that IE1-72 expression can bypass p107 function , we hypothesized
that IE1-72 induces p53 phosphorylation. Consistent with this supposition , our
results show that IE1-72 expression induces the phosphorylation of p53 at Ser
in MEFs. In addition to the wild-type MEFs, we examined the levels of phospho-
Ser p53 in p1gARF deficient MEFs expressing IE1-72. We observed a similar
outcome in the p1gARF-I- MEFs as compared to wild-type MEFs. These findings
suggest that the IE1-72-mediated phosphorylation of p53 at Ser occurs
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independent of p19ARF and most likely accounts for the increased levels of p53
protein observed in the p19' .RF-
/- 
MEFs following IE1-72 expression.
Besides affecting p53 protein levels, phosphorylation of p53 at Ser (the
human equivalent to Ser18 on mouse p53) alters p53 nuclear shutting (169). Our
findings demonstrate that IE1-72 expression promotes the nuclear retention of
p53. The inability of p53 to shuttle out of the nucleus in the presence of IE1-
may account for the accumulation of p53 in the nuclei of IE1-72-expressing cells
as described in the previous chapter. Moreover, the results from our
experiments using p53N/C, a mutant form of p53 in which all of serine residues
were changed to alanine residues , further supports the relationship between p53
II.
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phosphorylation and the regulation of p53 nuclear shuttling. Taken together
these observations suggest that phosphorylation of p53 at Ser
8 contributes to
II;
the increase and to the nuclear accumulation of p53 in IE1-72-expressing cells.
:1'
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IE1-72 has the ability to phosphorylate numerous cellular substrates
including p107 , p130, and the E2F proteins (1 , and 3) (111). Although IE1-
iq-
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appears to exhibit kinase activity, p53 has not been demonstrated as a direct
substrate (94 , 111). This lack of evidence implies that another kinase is
responsible for the phosphorylation of Ser on murine p53 and of Ser
5 on
human p53 following IE1-72 expression. Our results are consistent with this
notion because we find that treating cells with caffeine following IE1-
expression diminishes phosphorylation of p53 on Ser . Furthermore , these
findings imply that a caffeine-sensitive kinase phosphorylates p53 at Ser
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Indeed, we find that ATM is required for phosphorylation of p53 on Ser
5 (Ser
on murine p53) because this modification does not occur in IE1-72-expressing
cells from ataxia telangiectasia (AT) patients but does occur in IE1-72-expressing
cells from age and sex-matched normal individuals. In the absence of ATM , IE1-
72 also failed to alter total p53 levels suggesting that ATM plays an important
role in the ability of IE1-72 to induce p53 protein levels in the WT fibroblasts.
However, since we did not examine the effect of IE1-72 on p19
ARF protein in
either AT or WT fibroblasts, we cannot rule out the possibility that p19
ARF
contributes to part of the observed increase in p53 protein following IE1-
expression in the WT cells. Furthermore , the results from our analysis with the
WT cells suggest that the increase in phosho-Ser p53 levels following IE1-
expression is not due to an elevation in total p53 protein since the ratio of the
fold-change in phospho-Ser p53 to the fold-change in endogenous p53 was
greater than 1: 
A TM is a member of the phosphatidylinositol 3-kinase- like family and is a
primary signal transducer activated following DNA damage or double stranded
breaks (39). However, it is unclear how IE1-72 stimulates ATM activity. The
activation of A TM occurs in response to defects in the G , Gz , and S-phase
checkpoints (171). It is feasible that IE1-72 triggers ATM activity by modulating
one of these checkpoints through the inactivation of p107 and induction of E2F
activity. Additionally, IE1-72 has been described as being potentially mutagenic
possibly by blocking apoptosis (90 , 131). It is possible that IE1-72 expression
- - - - --. - - - - - - -- - - - - -  - -
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may act as a mutagen and somehow lead to DNA damage or activate
components of the DNA damage pathway including ATM. Moreover , IE1-
phosphorylates a number of cellular proteins (111). Therefore, it is conceivable
that IE1-72 directly phosphorylates and induces ATM thereby causing the
phosphorylation of ATM targets including p53. Finally, since ATM can
phosphorylate and activate other DNA damage- inducible kinases such as CHK1
and CHK2 , which also phosphorylate p53 at Ser
15 (or Ser ), it remains unclear
whether A TM directly or indirectly mediates this modification in cells following
IE1-72 expression.
HCMV induces p53 protein levels following infection in fibroblasts and
smooth muscle cells (69 104 140). Although it is unclear which viral proteins are
responsible for affecting p53 protein levels in infected cells , it appears that the
HCMV IE proteins playa role in modulating p53. In support of this inference , the
results presented in this chapter suggest that IE1-72 may be one of the proteins
that cause p53 protein levels to increase following HCMV infection. Because
IE1-72 is immediately expressed in cells following infection , the early increase in
p53 protein that is observed in HCMV- infected cells (69 , 104) may be attributed
to IE1-72. Moreover , as demonstrated in the previous chapter , IE1-
expression causes cells to undergo growth arrest in the presence p53 and this is
likely due to the inability of IE1-72 to block p53 function. Thus , we speculate that
IE1-72 may also play part in causing the HCMV-mediated growth arrest that is
observed in infected cells.
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Like IE1- , IE2-86 expression also modulates p53 protein levels. IE2-
stabilizes p53 protein by limiting its degradation (44). Additionally, IE2-86 can
bind to p53 and inhibit its transactivation function by tethering a transcriptional
repression domain to p53 (140 152). Therefore , it appears that IE2-86 increases
p53 protein levels in cells but can overcome the growth arrest response mediated
by p53. This may explain why IE2-86 expression induces S-phase and delay cell
cycle exit in p53 wild-type cells whereas IE1-72 cannot. Taken together, the
expression of IE 1-72 and I E2-86 causes an increase in p53 protein that may
account for the elevated p53 protein levels observed in HCMV- infected cells and
may contribute to the divergent effects mediated by HCMV on the host cell cycle.
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CHAPTER V
Consequences of p53 protein accumulation following IE1-72 expression
1. HCMV IE1-72 expression induces p21 expression
To determine the consequences of the p53 protein induction following IE1-
72 expression , we tested for the activation of a p53 transcriptional target.
Because p53 transactivates the expression of the p21 promoter upon activation
we determined whether IE1-72 expression activates the p21 promoter in reporter
assays. As shown in Figure 5. , a 17 -fold increase in p21 promoter-reporter
activity was observed following IE1-72 expression as compared to control
plasmid-transfected cells. We also examined p21 protein levels in p53+/+ MEFs
infected with either Ad1E1-72 or a control virus (AdCon). In contrast to our
Additionally, we detected p21 protein in cells infected with Ad1E1-72 or
lij
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reporter assay results , IE1-72 expression caused a nominal increase in p21
levels relative to that observed in control virus-infected cells (Figure 5.2).
gal and then performed immunohistochemical staining for p21 protein. We
quantified the number of p21-positive cells in each population (Figure 5. B).
Cells expressing IE1-72 exhibited a relatively higher percentage of p21-positive
cells (::50%) as compared to both the mock- infected and control virus- infected
cells where less than 30% of the population stained positive for p21 protein
during a 48 h time course (Figure 5. A). The percentage of p21-positive cells
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Figure 5. 1. IE1-72 activates expression of a p21-promoter reporter
.II!.
construct. !li:
Human lung fibroblasts were co-transfected with a p21- promoter reporter
construct , pWAF- Luc , and either an IE1-72 cDNA expressing construct
(pcDNA3- IE1-72) or a control plasmid (pcDNA3). A renilla luciferase plasmid
was also co-transfected as a normalization control for transfection efficiency in
our reporter assays. The averaged results from three separate assays and the
standard deviation derived from the mean are depicted in the figure.
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Figure 5.2. IE1-72 induces p21 protein.
Western blot analysis was performed on whole cell extracts from early passage
WT MEFs infected with either Ad1E1-72 or a control virus (AdCon) (MOl = 250).
Cells were harvested at 24 h p. i. p21 protein was detected with an anti-p21
polyclonal antibody. Actin levels were probed as a loading control.
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Figure 3. IE1-72 induces p21 protein accumulation.
Subconfluent cultures of REF52 cells were infected with either Ad1E1-72 or a
control virus (Ad gal) at the MOl indicated and then immunohistochemically
stained for p21 protein at 24 and 48 h post- infection. Mock-infected cells were
included as a negative control for our analysis to demonstrate the background
levels of p21 protein in the cells. REF52 cells infected with Adp53 (MOl = 20)
served as a positive control for p21 staining. The number of p21-positive cells
within the population of REF52 cells was quantitated. A minimum of 300 cells
was scored for each population. The results are presented as the percentage of
p21-positive cells within the population and represent the averages from three
separate analyses. Error bars represent the standard deviation derived from the
mean. (B) Number of p21- positive cells within populations of p53- MEFs
infected with either Ad1E1- 72 or a control virus (MOl = 250). p53- MEFs infected
with Adp53 (MOl = 20) served as a positive control for p21 staining. The result
from one representative experiment is shown.
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observed following IE1-72 expression was similar to that in cells expressing p53
which served as a positive control for this analysis. To confirm if the induction of
p21 protein following IE1-72 expression requires p53 , we conducted a similar
analysis in p53- MEFs. In the absence of p53 , there were very few p21-positive
cells observed following IE1-72 expression (Figure 5. B). As expected , p53
expression in the p53- MEFs caused an increase in the percentage of p21-
positive cells. Taken together, these findings suggest that IE1-72 expression
increases p21 levels through a p53-dependent mechanism.
2. HCMV IE1-72 expression induces quiescent cells to enter S-phase in the
absence of p21
We previously demonstrated that IE1-72 is unable to promote S-phase
entry in the presence of p53. Because p21 expression is activated by p53 and
p21 is required for p53-mediated growth arrest , we determined whether p21 was
necessary for the growth arrest phenotype induced by IE1-72 in wild-type cells by
testing the ability of IE1-72 to induce S- phase entry in quiescent WT and p21-
MEFs. We empirically optimized the conditions required to render the p21-
MEFs and their WT counterparts into quiescence (data not shown). As shown in
Figures 5.4A and B , culturing in 0.25% serum media for 48 h was sufficient to
induce growth arrest in over 80% of the WT and p2r MEFs infected with the
control virus. IE1-72 expression had no apparent effect on quiescent WT MEFs.
In the presence of p21 , only 5.5% of the IE1-72-expressing cells were in S-phase
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Figure 4. IE1-72 induces quiescent cells to enter S-phase in the absence
of p21.
Early passage WT and p21-/- MEFs were cultured in low serum to induce growth
arrest. Cells were then infected with Ad1E1-72 or a control virus and maintained
under low serum conditions. (A) At 24 h post- infection , the cells were harvested
and stained with PI. Flow cytometry analysis was performed and the percentage
of cells in S-phase was scored. Flow cytometry data is summarized as
histograms from each of the different MEF populations. The average percentage
of cells in S-phase from two separate experiments is represented as a histogram
for each cell type. (B) Cells were labeled with BrdU for 12 h prior to harvesting at
the indicated times post- infection. BrdU-positive cells were identified by
immunohistochemical staining using an anti-BrdU monoclonal antibody and the
number of BrdU-positive cells was scored. The averaged results from two
separate experiments are presented as the percentage of cells that stained
positive for BrdU incorporation. Error bars shown in (A) and (B) represent the
standard deviation derived from the mean.
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as compared to 6.8% observed in the control virus- infected cells (Figure 5.4-A).
We infected cells with AdE2F1 as a positive control for our experiment and as
expected , E2F1 expression induced the quiescent WT MEFs to enter S-phase as
evidenced by the increased percentage of cells in S-phase (17%) relative to the
control population.
In contrast, in the absence of p21, IE1-72 expression caused an increase
in the percentage of S-phase cells as compared to the control virus- infected
population (15. 1 % vs. 8.2%, respectively). As shown in Figure 5.4- , following
IE1-72 expression , the percentage of cells in S-phase was less than that
observed in the E2F1-expressing p21- MEFs (20.9%).
We also examined the levels of BrdU incorporated by quiescent WT and
p21- MEFs infected with Ad1E1-72 or AdCon and then labeled with BrdU. As
shown in Figure 5.4- , there was a similar percentage of BrdU-positive cells
observed in the IE1-72-expressing WT MEFs as compared to the control virus-
infected cells at both time points examined (48h: 15.5% vs. 14.6%, and 72h:
17.0% vs. 13.4%, respectively). In contrast, IE1- 72 expression in p21- MEFs
caused an increase in the percentage of BrdU-positive cells relative to the control
population (48h: 34.5% vs. 22. 1 %, and 72h: 35.5% vs. 25.4%, respectively).
Taken together, these results suggest that the inability of IE1-72 to induce
quiescent cells into S-phase is due to the activation of the p53/p21 growth arrest
pathway.
eO-
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3. HCMV IE1-72 expression delays cell cycle exit in the absence of p21
Because IE1-72 expression was not sufficient to induce S-phase entry in
the cells expressing p21 , we wanted to verify if the presence of p21 prevents IE1-
72 from delaying cell cycle exit following culture in reduced serum. To address
this, we infected WT and p2r MEFs with Ad1E1-72 or AdCon prior to serum
withdrawal and analyzed for BrdU incorporation. IE1-72 expression failed to
delay cell cycle exit in the WT MEFs (Figure 5.5). At 48 h , the percentage of
BrdU-positive cells observed in the IE1-72-expressing cell population was similar
to that of the control virus- infected cell populations (9.6% vs. 10.5%,
respectively).
Contrary to the observations with the WT MEFs , IE1-72 expression
delayed cell cycle exit in p21- MEFs following serum withdrawal. We observed a
higher percentage of BrdU-positive cells amongst the IE1-72-expressing cells as
compared to the control virus- infected cells such that almost 30% of the cells
expressing IE1-72 stained positive for BrdU incorporation as opposed to less
than 25% in the control population (35. 1 % vs. 22.2%, respectively). Additionally,
WT and p21-deficient MEFs infected with AdE2F1 served as a positive control for
our analysis and in both cell types; E2F1 expression delayed cell cycle exit in
both cell types. Overall , these observations are consistent with the results from
our cell cycle exit experiments in p53 wild-type and p53- MEFs and imply that
the p53/p21 pathway mediates the growth arrest phenotype induced by IE1-72.
- - -
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Figure 5.5. IE1-72 expression delays cell cycle exit in the absence of p21.
Early passage WT or p21-/- MEFs were infected with either AdCon or Ad1E1-
(MOI=250) and then cultured in media containing reduced serum. Cells were
pulsed with BrdU for 12 h prior to harvesting at 48 h p. i. Cells were
immunohistochemically stained for BrdU incorporation using an anti-BrdU
monoclonal antibody and the number of BrdU-positive cells was scored. The
result from one representative experiment is shown.
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4. Discussion
In the previous chapter, we demonstrated that IE1-72 appears to modulate
p53 protein levels by inducing p19ARF protein and the phosphorylation of p53 at
Ser 8 (Ser15 on human p53). Here , we report that IE1-72 induces p21 protein in
a p53-dependent manner and causes a p21-dependent growth arrest in cells
followi ng IE 1-72 expression.
Due to the fact that increases in p53 protein correlate with an increase in
its transcriptional activity, we examined the consequences of p53 induction
following IE1-72 expression. We focused our analysis on p21 due to the fact that
it plays a critical role as a downstream effector molecule in the p53-mediated
growth suppressive pathway. Specifically, the p21 protein functions as a cyclin-
dependent kinase inhibitor whose expression inhibits cell cycle progression (41
, 161). Because IE 1-72 expression causes growth arrest in wild-type cells , we
hypothesized that IE 1-72 expression alters p21 protein levels analogous to that
of p53 and that this contributes to the growth arrest phenotype observed in IE1-
72-expressing cells.
We employed three different assays to assess IE1-72 effect on p21
expression. Consistent with our hypothesis , we observed that IE1-72 induces
p21 protein expression. Although the levels of p21 protein detected in extracts
from IE1-72-expressing MEFs do not reflect the increased level of p21-promoter
activity observed following IE1-72 expression , the results from our
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immunohistochemical analyses support the notion that IE1-72 influences p21
protein levels in a p53-dependent manner.
One possible explanation for the disparity between the results from our
immunoblot analysis and our reporter assay is that p21 stability may be
compromised in IE1-72-expressing cells. Support for this hypothesis stems from
the fact that p21 levels fluctuate in HCMV- infected fibroblasts (27). HCMV
induces a temporary increase in p21 protein during IE times that precedes a drop
in p21 protein levels. The decrease in p21 protein following HCMV infection is
caused by the virus-mediated increase in calpain activity, which enhances the
degradation of p21 (27). While it is not apparent which HCMV protein is
responsible for increasing calpain activity in HCMV- infected cells , it is possible
that IE1-72 is the viral factor that promotes the calpain-mediated degradation of
p21 following infection. In this manner, IE1-72 induces p21 protein but at the
same time , may act to limit the levels of p21 protein in cells by facilitating its
degradation. Moreover , our observation that IE1-72 induces p21 protein raises
the possibility that IE 1-72 is responsible for (or contributes to) the induction of
p21 in HCMV- infected cells at IE times.
We extended our analysis to determine whether p21 plays a role in
abrogating the S-phase- inducing effect of IE1-72 in wild-type cells. In cells
lackingp53 , IE1-72 expression induces S-phase , and this is likely due to the
absence of a p53-mediated growth arrest response. Consistent with this
observation , we find that IE1-72 also induces S-phase in cells lacking p21. Thus
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it appears that p21 also plays a role in blocking the ability of IE 1-72 to promote S-
phase entry in quiescent cells as well as to delay cell cycle exit. Therefore , we
propose the following model in which IE1-72 induces p53 and this results in p21
protein induction. The end result to this chain of events is a p53-mediated
growth arrest and this accounts for the growth arrest phenotype previously
described for the IE1-72-expressing cells in Chapter III.
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CHAPTER VI
Discussion
A. Thesis Overview
The initial goal of this study was to determine whether the HCMV IE
proteins , IE1-72 and IE2- , could modulate the cell cycle in a manner similar to
the oncoproteins of the small DNA tumor viruses. There is existing evidence that
the small DNA tumor viruses can alter the cell cycle to facilitate the efficient
replication of their viral DNA. The ability of adenovirus , SV- , and HPV to
manipulate the cell cycle is dependent upon the expression of viral oncoproteins
that neutralize the function of p53 and the RB family of proteins (108). Both
HCMV IE1-72 and IE2-86 exhibit similar properties to the small DNA tumor virus
oncoproteins in their ability to target RB family members. Binding of IE1-72 and
IE2-86 to their respective RB target alleviates the repression of E2F-responsive
genes and the growth suppressive effects mediated by pRb and p107 (43, 116).
Additionally, IE2-86 binds to p53 and inhibits its transactivation function (16 , 140
152). Given the functional similarities between the HCMV major IE proteins and
the small DNA tumor virus oncoproteins, we hypothesized that IE1-72 and IE2-
expression alters cell cycle regulation in cells.
The data presented in this thesis demonstrate that expression of the
HCMV IE proteins can indeed alter cell cycle control. Specifically, IE2-
expression is sufficient to drive cells out of quiescence and into S-phase as well
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as delay cells from exiting the cell cycle into Go. IE1-72 can mediate a similar
effect as IE2-86 but only in cells lacking either pS3 or p21. IE1-72 induces the
nuclear accumulation of pS3 and this IE1-72-mediated induction of pS3 protein
correlates with its inability to induce S-phase entry and delay cell cycle exit in the
presence of pS3. The data also show that IE1-72 expression alters pS3 protein
levels by affecting the p19ARF/MDM2/pS3 pathway and by activating the ATM
kinase , a component of the DNA damage response , to induce the covalent
modification of pS3 , which also promotes pS3 nuclear retention.
B. HCMV IE proteins
Our observation that IE2-86 induces cells to enter S-phase was
contemporary to the findings reported by other groups (10S, 160) and is
consistent with the outcome one would expect from IE2-86 inactivating pRb
protein. IE2-86 induces E2F activity as evidenced by the multitude of E2F-
responsive genes that are activated in IE2-86-expressing cells (136). Among the
genes that are activated following IE2-86 expression are cellular factors that
regulate the cell cycle, function in nucleotide biosynthesis, and mediate the
initiation of cellular DNA synthesis. Additionally, IE2-86 directly activates cyclin E
gene expression (17), which is essential for progression of the cell cycle into S-
phase. The IE2-86-mediated elevation in cyclin E levels and concomitant
increase in cyclin E-cdk2 activity may enhance the phosphorylation of pRb and
contribute towards the further induction of E2F activity. Thus , these findings
- -
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support the notion that IE2-86 promotes cell cycle progression towards the G
transition point and entry into S-phase.
Because IE1-72 interacts with p107 and can alleviate the p107-mediated
repression of E2F-responsive promoters (116), one would predict that like IE2-
, IE1-72 should induce E2F activity. IE1-72 expression stimulates transcription
from the promoters of several E2F-responsive genes such as DHFR and DNA
polymerase a (59 94). Therefore , it appears that IE1-72 can induce E2F activity;
however, it is unclear whether IE1-72 can activate other E2F-responsive genes.
Given the large number of genes that contain E2F-responsive elements in their
promoter sequence, I speculate that IE1-72 affects the expression of many other
E2F-specific genes. Moreover , there is a high probability that some degree of
overlap exists between the E2F-responsive genes activated by IE1-72 and IE2-
86. Hence , the ability of the HCMV IE proteins to induce E2F activity and the
concomitant activation of factors associated with the cellular DNA replication
machinery emphasizes their similarity to the small DNA tumor virus oncoproteins.
Since p107-E2F complexes accumulate at or near the G /S boundary
(177), one would hypothesize that the disruption of these complexes by IE1-
should promote S-phase entry. IE1-72 can induce S-phase entry, but only in the
absence of either p53 or p21. The fact that IE1-72 promotes S-phase entry in
cells deficient for either protein underscores the inability of IE1-72 to block p53
activity, which in this case results in growth arrest. The importance of overcoming
p53-mediated arrest is exemplified by our findings from the cell cycle
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experiments conducted in WT cells expressing IE2-86. In the presence of p53
IE2-86 can induce S-phase entry and I suspect that this may be attributed in part
to its capacity to inhibit p53 activity (140, 152). The ability of IE2-86 to block p53-
mediated growth arrest most likely stems from the p53-repression domains
present on IE2-86 (152). As shown in Figure 1. , the p53-repression domains
(aa 45 to 135; aa 290 to 579) contain sequences that originate from exon 5 of the
IE2-86 transcript and are unique to IE2-86. This probably accounts for the
divergent effects exhibited by each of the HCMV IE proteins on p53 activity
where IE2-86 expression can overcome p53-mediated growth arrest whereas
IE1-72 cannot. Overall , these findings imply that p53 acts as an important hurdle
that must be bypassed in order to transit G1 to S-phase.
C. Proposed model for the effect of the HCMV IE proteins on cell cycle control
Based on the data presented in this thesis , I propose the following model
to account for the effect of IE1-72 and IE2-86 on the cell cycle (Figure 6. 1). Both
IE1-72 and IE2-86 inactivate certain RB family members and consequently
induce E2F activity. E2F induction results in the activation of S-phase genes and
promotes the subsequent entry of cells into S-phase. As demonstrated in my
thesis, IE1-72 expression promotes p53 protein accumulation and this leads to
the induction of p21 protein. As a consequence of these events , IE1-72 is not
able to induce S-phase entry. The IE1-72-mediated induction of p53 protein
coupled with the inability of IE1-72 to override p53 activity, effectively masks the
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Figure 6.1. Model ilustrating the effect of HCMV IE proteins on cell cycle
control.
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growth promoting effects of IE1-72 and may account for the growth arrest
phenotype observed when IE1-72 is expressed in WT cells (Chapters III and V).
IE2-86 also promotes p53 protein accumulation. In contrast to IE1-
IE2-86 can interact with p53 and down regulate its activity (140 , 152). Moreover
a recent study showed that IE2-86 also binds to p21 and represses its cyclin-
dependent kinase inhibitor activity (132). Thus , the ability of IE2-86 to block p53
function , as well as inhibit the activity of one of its downstream target proteins
(i.e. p21), may allow the S-phase promoting activity of IE2-86 to take place
unimpeded.
Our findings suggest that IE1-72 and IE2-86 can modulate the cell cycle
towards an " phase-like" environment, however it is unclear why HCMV
encodes two separate IE gene products to mediate this effect. One possible
explanation is that HCMV expresses IE1-72 and IE2-86 in order to maintain an
phase- like" environment throughout the course of infection. Because IE1-
is the predominant IE gene product that is initially expressed following infection
the expression of IE1-72 may promote an " phase- like" environment in the host
cell during the early course (i.e. the first 24 h) of infection. However, since IE1-
72 expression may also contribute to both the early increase in p53 protein
following HCMV infection as well as the growth arrest that is observed in some
HCMV- infected cells , the " phase- like environment" that is induced by IE1-
may be negated. On the contrary, IE2- , through its ability to block p53 and
p21 function , may offset the growth arrest induced by IE1-72 and cause the
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infected cells to maintain this " phase- like" state. Detectable levels of IE2-
can be seen as early as 24 h post infection. Since IE2-86 expression is delayed
relative to that of IE1- , one would expect the " phase- like environment"
mediated by IE2-86 to prevail during the latter course (:: 24 h) of infection. Taken
together, these events may account for the differential effects mediated by
HCMV on the cell cycle.
D. Relevance to HCMV biology
1. HCMV and proliferative disease
Despite the evidence presented in this thesis that expression of the HCMV
IE proteins can alter cell cycle control , HCMV does not appear to be oncogenic.
However , the virus exhibits the capacity to transform certain types of cells in vitro
, 15 , 48). Although it is unclear how HCMV transforms these cells , it has been
speculated that IE1-72 and IE2-86 playa role in this process by possibly causing
genetic instability (90, 131). While there is no clear evidence that expression of
the IE proteins causes DNA damage in vivo HCMV can induce specific breaks
on chromosome 1 at the 1 q42 and 1 q21 loci (42). This virus- induced damage is
believed to occur while the cells are in S- or G /M-phase. As demonstrated in my
thesis, the IE proteins have the capacity to induce cells past the G /S transition
point. Moreover, I show that IE1-72 activates the ATM kinase , a primary signal
transducer that is triggered following DNA damage or double strand breaks (39).
Although it is unclear how IE1-72 induces A TM activity, the activation of this
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kinase may signify DNA damage incurred by cells following IE1-72 expression.
Thus , in addition to driving cells towards an " phase- like" environment , the IE
proteins may inadvertently induce chromosome damage within the HCMV-
infected cell.
There is evidence that implies a link between HCMV and the development
of restenosis , a proliferative disorder linked to coronary angioplasty that is
characterized by the overproliferation and increased migration of SMCs to the
blood vessel injury site. HCMV seropositive patients are more likely to develop
restenosis following balloon angioplasty as compared to HCMV seronegative
patients (173). In addition , HCMV DNA and protein can be detected in SMCs
grown from restenotic lesions. In fact, IE2-86 protein has been detected in
lesions taken from restenosis patients (140). Our findings provide a possible
mechanism to account for how the IE proteins may contribute to the
overproliferation of SMCs that is characteristic of this proliferative disorder.
Expression of the IE proteins in newly- infected SMCs or following HCMV
reactivation in latently infected SMCs in vivo may promote deregulated
proliferation of these cells by either inducing them to enter S-phase or by
hindering their ability to undergo quiescence. In both instances , the SMCs would
continue to proliferate , and this may subsequently lead to the over-accumulation
of SMCs along the vessel wall indicative of restenosis.
Although the perturbation of cell cycle control appears to be one of the
ways that HCMV may contribute towards the development of restenosis, other
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virus-mediated events seem to playa role in this disorder. It is well accepted that
the accumulation of SMCs along the vessel wall is attributed to complex
mechanisms that include factors influencing both SMC proliferation and
migration. HCMV induces the expression of several cytokines that may enhance
the proliferation of SMCs. lt has been suggested that HCMV may indirectly
enhance SMC migration by increasing the expression of the PDGF receptor in
infected SMCs (175). The virus also directly promotes SMC migration through
the expression of the US28 gene product , an HCMV-encoded chemokine
receptor (148). The expression of this chemokine receptor, coupled with the
release of many chemokines that activate the Us28 protein , may induce the
infected SMCs to migrate and localize to the site of injury along the vessel wall.
Taken together, these observations provide a plausible link between HCMV and
the development of restenosis and offer an explanation as to how the virus can
contribute to both the overproliferation and accumulation of SMCs along the
vessel wall.
2. Significance to HCMV DNA replication
From the standpoint of HCMV infecting a cell , it is imperative to generate
an environment that is conducive for viral DNA replication. Analogous to the
small DNA tumor viruses , HCMV normally infects quiescent , non-cycling cells 
vivo; cells that have a limited quantity of deoxyribonucleotides and co-factors
available for the replication of viral or cellular DNA. This presents an unfavorable
condition for viral DNA replication. To offset this situation , HCMV expresses
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several proteins that can alter the cell cycle towards a more favorable
environment , S-phase (Figure 6.2A; top panel). As demonstrated in my thesis
two of the HCMV IE gene products exhibit the capacity to alter cell growth control
towards S-phase. In addition to IE1-72 and IE2- , the ability of HCMV to
stimulate the cellular replication machinery towards an S-phase- like environment
may be due in part to the pp71 tegument protein , which can also induce cells to
enter S-phase (74). One might predict that the presence of these viral proteins in
HCMV- infected cells should promote cell cycle progression towards S-phase.
Indeed, many of the events that are associated with the progression through G
and entry into S-phase are observed in HCMV- infected cells. However S-phase
as measured by host DNA replication does not occur in these cells. Rather , S-
phase progression , or at least cellular DNA replication , is interrupted and this
may be due to the effect of viral proteins that have a negative impact on the host
cell cycle (Figure 6.2A; bottom panel). As shown in Chapters III and IV , IE1-
induces p53 and this appears to result in a p53-mediated growth arrest in IE1-72-
expressing cells. In addition to IE1- , the pUL69 protein induces cells to growth
arrest in late G1 or alternately, specifically inhibits cellular DNA replication (89).
Through this strategy, which may well involve other viral proteins, HCMV
activates host cell factors that appear to facilitate the replication of the viral
genome and also ensures that replication of viral DNA rather than cellular DNA
occurs within the infected cell as has been observed (19 , 35 , 69 , 88).
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Figure 2. Model ilustrating the effect of HCMV on the cell cycle.
(A) Schematic representation of the HCMV viral gene products and the host cell
factors that they target. Also shown are the putative effects mediated by IE1-
IE2- , pp71 , and pUL69 on the cell cycle to promote the transition from G /G1 to
and into early S-phase. See text for details. (B) Graph representing the
relative proteins levels (shown on the Y-axis) of HCMV IE1- , IE2- , pUL69
and pp71 that are observed during the course of an HCMV infection.
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To ensure that an environment favoring viral DNA synthesis is maintained
within the infected host cell , HCMV expresses multiple gene products that can
alter the cell cycle at different times throughout the duration of the infection
(Figure 6-2B). pp71 and pUL69 may be the first proteins to affect the host cell
cycle during an HCMV infection. Both tegument proteins are released into the
host cell following virus binding and entry. The pp71 protein may serve as the
initial stimulus that drives the infected cell into S-phase whereas the pUL69
protein may counter this effect by causing the cell to arrest in early S-phase.
Following virus entry, pp71 and pUL69 degrade and as a result, their opposing
effects on the cell cycle wane during the immediate early phase of infection.
However, IE1-72 expression also occurs at this time and this may prolong the
block in the cell cycle due to the ability of IE1-72 to promote S-phase entry while
inducing growth arrest. Subsequent to IE1- , IE2-86 expression takes place
and since IE2-86 can activate numerous factors required for DNA synthesis as
well as drive cells into S-phase , one might expect cellular DNA replication to
occur within the infected cell. Concomitantly, expression of the early gene
product , pp71 , also occurs during this time and this event may augment the S-
phase promoting effect mediated by IE2-86 during the early phase of an HCMV
infection. In spite of this , the continued expression of IE1-72 along with the early
gene product , pUL69 , may impede the putative S-phase progression mediated
by IE2-86 and pp71 and cause an S-phase arrest in the host cell that persists
through the early and late phases of infection. By this process , HCMV may
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enhance the replication of its DNA by activating the host cell components needed
for DNA synthesis while deterring cellular DNA replication.
It is clear that HCMV mediates divergent effects on the cell cycle (23 , 74)
and this may be attributed to the expression of the abovementioned viral gene
products that can modulate the host cell cycle. HCMV infection causes human
fibroblasts to arrest in what was thought to be late G or Gz/M (19 , 35 , 69 , 88).
Although the virus induces what is characterized as a " arrest" in infected
human fibroblasts , biochemically these cells exhibit hallmarks of S-phase that
include pRb hyperphosphorylation , elevated levels of cyclin E , cyclin B , and
PCNA, and increased cyclin E and cyclin A kinase activity (19 , 35 , 69). The
expression of several S-phase genes including DHFR , DNA polymerase a , and
topoisomerase II are also observed in HCMV-infected fibroblasts. In addition
recent evidence indicates that HCMV can induce S-phase in other cell types
including monocytes and smooth muscle cells (132 , 175), which are among the
cells targeted by HCMV in vivo. Given the activation of S-phase associated
factors and induction of S-phase entry in spite of the block in host cell DNA
replication , it appears that HCMV may be inducing an "early S-phase arrest"
rather than a G1 arrest. By arresting cells during the stage of the cell cycle when
the factors associated with DNA replication are at their peak, HCMV may provide
a more favorable environment for viral DNA replication. In this manner , HCMV
DNA replication may resemble that of the small DNA tumor viruses.
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E. Viruses and the cell cycle
1. Small DNA viruses
Adenovirus and SV-40 serve as good paradigms for how the small DNA
viruses can modulate the host cell cycle to achieve their overall goal: to replicate
their viral DNA. Because both of these viruses lack accessory factors that
support DNA replication , adenovirus and SV-40 virus have evolved a strategy to
deregulate the normal control of S-phase in order to induce the cellular genes
necessary for DNA replication (121).
2. Herpesviruses
Contrary to the small DNA viruses , the larger DNA viruses , such as the
herpesviruses , appear to have a more complex relationship with the cell cycle.
HSV , an alphaherpesvirus , induces cells to growth arrest and blocks cellular
DNA synthesis (30, 40 , 134). HCMV , which is a betaherpesvirus, mediates a
divergent effect on the host cell cycle through its ability to activate factors
necessary for DNA synthesis while blocking cell cycle progression and inhibiting
host DNA replication. In contrast to HSV and HCMV , the absence of an efficient
lytic replication system for the gammaherpesviruses , such as EBV , makes it
difficult to fully assess the viral-mediated effects on the cell cycle. However
treatment of latent EBV-infected B-Iymphocytes with lytic cycle- inducing agents
induces cells to growth arrest (47 , 119). Moreover, each of the above-
mentioned herpesviruses encodes a protein(s) that is capable of inhibiting the
cell cycle. HSV expresses two proteins, ICPO and ICP27 , which inhibit the cell
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cycle at G (62 , 13S). HCMV also expresses at least two gene products , IE1-
72 (as shown in Chapters III and V) and pUL69 (89), that can cause cells to
growth arrest. Expression of the EBV lytic protein , BZLF1 , also blocks the cell
cycle (2S). Thus , it seems that inhibiting the host cell cycle is a significant step in
herpesvirus replication.
One could argue that herpesvirus DNA replication is not cell cycle
dependent because these viruses cause cells to growth arrest. Additional
support for the notion that herpesvirus DNA replication is cell cycle independent
stems from the fact that unlike the small DNA tumor viruses, the herpesviruses
encode factors that support viral DNA synthesis. All of the herpesviruses
express a large assortment of enzymes involved in nucleic acid metabolism
including thymidine kinase , thymidylate synthetase , ribonucleotide reductase
and dUTPase as well as factors that playa role in viral DNA replication (DNA
polymerase, helicase , and primase) (121). Experiments using specific HSV-
deletion mutants provide additional evidence that viral DNA replication is not
entirely dependent on the cell cycle. Infection with HSV mutants that fail to
express ICPO , thymidine kinase , or ribonucleotide reductase fail to replicate in
growth-arrested cells but can replicate to wild-type levels in cycling cells (21 , SO
68) implying that HSV replication is not dependent on the cell cycle.
Contrary to this argument , it seems that certain S-phase-associated
factors are necessary for the replication of several herpesviruses. For example
viral DNA synthesis by HSV and HCMV is inhibited in the presence of
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roscovitine , a Cdk inhibitor, or in cells expressing a dominant negative form of
Cdk2 (18 , 127) suggesting that Cdk2 activity is required by these viruses for DNA
replication. However, this does not rule out the possibility that other Cdks may
be necessary for HSV and HCMV DNA synthesis. In addition to the apparent
requirement for Cdk2 activity, topoisomerase II may also needed for the efficient
replication of some herpesviruses. Both topoisomerases I and II are required for
EBV lytic replication (78). HCMV induces the expression of cellular
topoisomerase II and the treatment of HCMV- infected cells with a topoisomerase
II inhibitor blocks viral DNA replication (13). These findings suggest that
topoisomerase II might be essential for both EBV and HCMV replication. In light
of the cell cycle block mediated by the herpesviruses
, it appears that these
viruses require the activation of S-phase to efficiently replicate. Taken together
these findings suggest that for some herpesviruses such as HCMV and EBV
viral DNA replication may be cell cycle dependent.
Furthermore , targeting of the RB proteins and p53 by certain
herpesviruses implies a link between viral DNA replication and the cell cycle.
HCMV IE1-72 and IE2-86 can each interact with RB family members (43
116). IE2-86 can also bind to p53 and inhibit its ability to transactivate p53-
responsive promoters (140 , 152). Similarly, EBV encodes two IE gene products
that target pRb and p53. The EBV BRLF1 protein binds to pRb and induces free
E2F levels (166) and transient expression of BRLF1 is sufficient to induce S-
phase in quiescent cells (149). The BZLF1 protein binds p53 and abrogates its
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transactivation function (167). Alternatively, KSHV encodes a viral cyclin
(vCYC) that associates with cellular CDK6 that can phosphorylate RB proteins as
well as activate cyclin A expression (26
, 38 84). In addition , the
gammaherpesviruses express several latency-associated viral gene products
that potently alter cell cycle regulation , which most likely contribute to the ability
of these viruses to transform cells following infection (78). Overall
, targeting and
inactivation of the key cell cycle regulatory proteins by several herpesvirus
proteins imply a connection between modulating the cell cycle and virus
replication.
The replication of the small DNA tumor viruses such as adenovirus and
SV- , is dependent on their ability to induce quiescent cells to enter S-phase.
Parvovirus , which is the smallest DNA animal virus known to man
, only replicates
when infected cells enter S-phase (106). These small DNA viruses utilize cellular
factors that become or are active during S-phase. The replication of some large
DNA viruses , such as the herpesviruses , appears to follow a similar pattern. As
mentioned earlier, herpesvirus replication is dependent on the availability of
certain S-phase associated factors in infected cells. Therefore
, it appears that
large DNA viruses , as represented by the herpesviruses , share an important trait
with the small DNA viruses , that is the need to activate some components of the
host cell replication machinery to ensure efficient virus replication.
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F. Concluding remarks
The data presented in this thesis demonstrate how the HCMV IE proteins
IE1-72 and IE2- , can alter cell cycle control. The contribution of HCMV IE
proteins to the divergent effects of HCMV on the cell cycle has been addressed.
In addition , the potential role of the IE proteins in the development of restenosis,
a proliferative disorder that is linked to HCMV infection , has been described.
Furthermore , evidence has been provided suggesting that like the small DNA
viruses , some large DNA viruses require factors present during S-phase, to
facilitate efficient virus replication. Because HCMV encodes gene products that
can manipulate the host cell cycle in a multitude of ways including: promoting S-
phase , inhibiting host DNA synthesis , and preventing infected cells from arresting
in G1 or undergoing apoptosis , I believe that HCMV serves as a good paradigm
that represents the complex relationship between large DNA viruses, such as the
herpesviruses, and the cell cycle.
, I
138
Chapter VII
References
Adam, E. , J. L. Melnick, J. L. Probtsfield, B. L. Petrie, J. Burek, K. 
Bailey, C. H. McCollum, and M. E. DeBakey. 1987. High levels of
cytomegalovirus antibody in patients requiring vascular surgery for
atherosclerosis. Lancet 2:291-
Ahn , J. H. , and G. S. Hayward. 2000. Disruption of PML-associated
nuclear bodies by IE1 correlates with efficient early stages of viral gene
expression and DNA replication in human cytomegalovirus infection.
Virology 274:39-55.
Ahn , J. H. , and G. S. Hayward. 1997. The major immediate-early
proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt
PML-associated nuclear bodies at very early times in infected permissive
cells. J Virol 71 :4599-613.
Ahn , J. H. , W. J. Jang, and G. S. Hayward. 1999. The human
cytomegalovirus IE2 and UL 112-113 proteins accumulate in viral DNA
replication compartments that initiate from the periphery of promyelocytic
leukemia protein-associated nuclear bodies (PODs or ND1 0). J Virol
73:10458-71.
Albrecht , T. , M. Nachtigal , S. C. St Jeor, and F. Rapp. 1976. Induction
of cellular DNA synthesis and increased mitotic activity in syrian hamster
11.
12.
139
embryo cells abortively infected with human cytomegalovirus. J Gen Virol
30:167-77.
Albrecht, T., and F. Rapp. 1973. Malignant transformation of hamster
embryo fibroblasts following exposure to ultraviolet- irradiated human
cytomegalovirus. Virology 55:53-61.
Almeida-Porada, G. , C. D. Porada, J. D. Shanley, and J. L. Ascensao.
1997. Altered production of GM-CSF and IL-8 in cytomegalovirus- infected
IL- primed umbilical cord endothelial cells. Exp Hematol 25: 1278-85.
Ashcroft, M., M. H. Kubbutat, and K. H. Vousden. 1999. Regulation of
p53 function and stability by phosphorylation. Mol Cell Bioi 19: 1751-
Ashcroft, M. , Y. Taya, and K. H. Vousden. 2000. Stress signals utilize
multiple pathways to stabilize p53. Mol Cell Bioi 20:3224-33.
10. Banin, S. , L. Moyal , S. Shieh , Y. Taya, C. W. Anderson , L. Chessa , N.
I. Smorodinsky, C. Prives, Y. Reiss, Y. Shiloh , and Y. Ziv. 1998.
Enhanced phosphorylation of p53 by A TM in response to DNA damage.
Science 281:1674-
Bargonetti , J. , I. Reynisdottir, P. N. Friedman , and C. Prives. 1992.
Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40
T antigen and mutant p53. Genes Dev 6: 1886-98.
Bates , S. , A. C. Philips , P. A. Clark, F. Stott, G. Peters, R. L. Ludwig,
and K. H. Vousden. 1998. p14ARF links the tumour suppressors RB and
p53. Nature 395: 124-
18.
19.
20.
140
13. Benson , J. D. , and E. S. Huang. 1990. Human cytomegalovirus induces
expression of cellular topoisomerase II. J Virol 64:9-15.
14. Blasina , A. , B. D. Price, G. A. Turenne
, and C. H. McGowan. 1999.
Caffeine inhibits the checkpoint kinase ATM. Curr Bioi 9:1135-
15. Boldogh, I., E. Gonczol
, and L. Vaczi. 1978. Transformation of hamster
embryonic fibroblast cells by UV- irradiated human cytomegalovirus. Acta
Microbiol Acad Sci Hung 25:269-75.
16. Bonin, L. R.
, and J. K. McDougall. 1997. Human cytomegalovirus IE2
86-kilodalton protein binds p53 but does not abrogate G1 checkpoint
function. J ViroI71:5861-70.
17. Bresnahan , W. A. , T. Albrecht, and E. A. Thompson. 1998. The cyclin
E promoter is activated by human cytomegalovirus 86-kDa immediate
early protein. J Bioi Chem 273:22075-82.
Bresnahan , W. A. , I. Boldogh , P. Chi, E. A. Thompson
, and T.
Albrecht. 1997. Inhibition of cellular Cdk2 activity blocks human
cytomegalovirus replication. Virology 
231 :239-47.
Bresnahan , W. A. , I. Boldogh, E. A. Thompson
, and T. Albrecht. 1996.
Human cytomegalovirus inhibits cellular DNA synthesis and arrests
productively infected cells in late G1. Virology 224:150-60.
Bresnahan , W. A. , E. A. Thompson, and T. Albrecht. 1997. Human
cytomegalovirus infection results in altered Cdk2 subcellular localization. J
Gen Virol 78 (pt 8):1993-
21.
22.
23.
24.
25.
141
Cai , W. , and P. A. Schaffer. 1991. A cellular function can enhance gene
expression and plating efficiency of a mutant defective in the gene for
ICPO , a transactivating protein of herpes simplex virus type 1. J Virol
65:4078-90.
Canman, C. E. , D. S. Um , K. A. Cimprich , Y. Taya, K. Tamai, K.
Sakaguchi, E. Appella, M. B. Kastan , and J. D. Silciano. 1998.
Activation of the A TM kinase by ionizing radiation and phosphorylation of
p53. Science 281:1677-
Castilo, J. P. , and T. F. Kowalik. 2002. Human cytomegalovirus
immediate early proteins and cell growth control. Gene 290:19-34.
Caswell , R., C. Hagemeier, C. J. Chiou, G. Hayward, T. Kouzarides,
and J. Sinclair. 1993. The human cytomegalovirus 86K immediate early
(IE) 2 protein requires the basic region of the TAT A-box binding protein
(TBP) for binding, and interacts with TBP and transcription factor TFIIB via
regions of IE2 required for transcriptional regulation. J Gen ViroI74:2691-
Cayrol , C., and E. K. Flemington. 1996. The Epstein-Barr virus bZIP
transcription factor Zta causes GO/G1 cell cycle arrest through induction 
cyclin-dependent kinase inhibitors. EMBO J 15:2748-59.
26. Chang, Y. , P. S. Moore , S. J. Talbot, C. H. Boshoff, T. Zarkowska, K.
Godden, H. Paterson , R. A. Weiss, and S. Mittnacht. 1996. Cyclin
encoded by KS herpesvirus. Nature 382:410.
27.
28.
29.
30.
31.
32.
142
Chen , Z. , E. Knutson , A. Kurosky, and T. Albrecht. 2001. Degradation
of p21 cip1 in cells productively infected with human cytomegalovirus. J
ViroI75:3613-25.
Cherrington, J. M. , and E. S. Mocarski. 1989. Human cytomegalovirus
ie1 transactivates the alpha promoter-enhancer via an 18-base-pair repeat
element. J Virol 63:1435-40.
Chiou, C. J. , J. Zong, J. Waheed, and G. S. Hayward. 1993.
Identification and mapping of dimerization and DNA-binding domains in
the C terminus of the IE2 regulatory protein of human cytomegalovirus. J
ViroI67:6201- 14.
de Bruyn Kops , A. , and D. M. Knipe. 1988. Formation of DNA replication
structures in herpes virus- infected cells requires a viral DNA binding
protein. Cell 55:857-68.
de Stanchina , E. , M. E. McCurrach, F. Zindy, S. Y. Shieh , G. Ferbeyre
A. V. Samuelson , C. Prives, M. F. Roussel , C. J. Sherr, and S. W.
Lowe. 1998. E1A signaling to p53 involves the p19(ARF) tumor
suppressor. Genes Dev 12:2434-42.
DeGregori , J., Kowalik, TF., Nevins, JR. 1995. Cellular targets for
activation by the E2F1 transcription factor include DNA synthesis and
G1/S regulatory genes. Mol Cell Bioi 15:4215-4224.
37.
38.
39.
143
33. DeGregori , J. , Leone , G. , Miron , A. , Jakol , L., Nevins , JR. 1997.
Distinct roles for E2F proteins in cell growth control and apoptosis. Proc
Natl Acad Sci USA 94:7245-7250.
34. Dey, D. , J. Dahl , S. Cho , and T. L. Benjamin. 2002. Induction and
Bypass of p53 during Productive Infection by Polyomavirus. J Virol
76:9526-32.
35. Dittmer, D., and E. S. Mocarski. 1997. Human cytomegalovirus infection
inhibits G1/S transition. J Virol 71: 1629-34.
36. Donehower, L. A. , M. Harvey, B. L. Slagle , M. J. McArthur, C. A.
Montgomery, Jr. , J. S. Butel , and A. Bradley. 1992. Mice deficient for
p53 are developmentally normal but susceptible to spontaneous tumours.
Nature 356:215-21.
Doniger, J. , S. Muralidhar
, and L. J. Rosenthal. 1999. Human
cytomegalovirus and human herpesvirus 6 genes that transform and
transactivate. Clin Microbiol Rev 12:367-82.
Duro, D., A. Schulze, B. Vogt, J. Bartek
, S. Mittnacht, and P. Jansen-
Durr. 1999. Activation of cyclin A gene expression by the cyclin encoded
by human herpesvirus- 8. J Gen Virol 80 ( pt 3):549-55.
Durocher, D., and S. P. Jackson. 2001. DNA- , ATM and ATR as
sensors of DNA damage: variations on a theme? Curr Opin Cell Bioi
13:225-31.
40.
41.
42.
43.
44.
45.
144
Ehmann, G. L., T. J. McLean , and S. L. Bachenheimer. 2000. Herpes
simplex virus type 1 infection imposes a G(1 )/S block in asynchronously
growing cells and prevents G(1) entry in quiescent cells. Virology 267:335-
49.
el-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons , J.
M. Trent, D. Un , W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993.
WAF1 , a potential mediator of p53 tumor suppression. Cell 75:817-25.
Fortunato, E. A. , M. L. Dell'Aquila, and D. H. Spector. 2000. Specific
chromosome 1 breaks induced by human cytomegalovirus. Proc Natl
Acad Sci USA 97:853-
Fortunato, E. A. , M. H. Sommer, K. Yoder, and D. H. Spector. 1997.
Identification of domains within the human cytomegalovirus major
immediate-early 86-kilodalton protein and the retinoblastoma protein
required for physical and functional interaction with each other. J Virol
71 :8176-85.
Fortunato , E. A. , and D. H. Spector. 1998. p53 and Rpa are sequestered
in viral replication centers in the nuclei of cells infected with human
cytomegalovirus. J Virol 72:2033-
Freedman , D. A. , and A. J. Levine. 1998. Nuclear export is required for
degradation of endogenous p53 by MDM2 and human papillomavirus E6.
Mol Cell Bioi 18:7288-93.
46.
47.
48.
49.
50.
51.
145
Fuchs, S. Y. , V. Adler, T. Buschmann , X. Wu , and Z. Ronai. 1998.
Mdm2 association with p53 targets its ubiquitination. Oncogene 17:2543-
Fukuda, M., T. A. Satoh, M. Takanashi, K. Hirai , E. Ohnishi, and T.
Sairenji. 2000. Inhibition of cell growth and Epstein-Barr virus reactivation
by CD40 stimulation in Epstein-Barr virus-transformed B cells. Viral
ImmunoI13:215-29.
Geder, K. M., R. Lausch , F. O'Neil , and F. Rapp. 1976. Oncogenic
transformation of human embryo lung cells by human cytomegalovirus.
Science 192:1134-
Godden-Kent, D. , S. J. Talbot, C. Boshoff, Y. Chang, P. Moore, R. A.
Weiss, and S. Mittnacht. 1997. The cyclin encoded by Kaposi's sarcoma-
associated herpesvirus stimulates cdk6 to phosphorylate the
retinoblastoma protein and histone H 1. J Virol 71 :4193-
Goldstein , D. J. , and S. K. Weller. 1988. Factor(s) present in herpes
simplex virus type 1- infected cells can compensate for the loss of the large
subunit of the viral ribonucleotide reductase: characterization of an ICP6
deletion mutant. Virology 166:41-51.
Gonczol , E. , and S. A. Plotkin. 1984. Cells infected with human
cytomegalovirus release a factor(s) that stimulates cell DNA synthesis. J
Gen Virol 65 (pt 10):1833-
54.
55.
56.
57.
146
52. Grattan, M. T., C. E. Moreno-Cabral, V. A. Starnes, P. E. Oyer, E. B.
Stinson, and N. E. Shumway. 1989. Cytomegalovirus infection is
associated with cardiac allograft rejection and atherosclerosis. JAMA
261 :3561-
53. Greaves, R. F. , and E. S. Mocarski. 1998. Defective growth correlates
with reduced accumulation of a viral DNA replication protein after low-
multiplicity infection by a human cytomegalovirus ie1 mutant. J Virol
72:366-79.
Hagemeier, C., R. Caswell , G. Hayhurst, J. Sinclair, and T.
Kouzarides. 1994. Functional interaction between the HCMV IE2
transactivator and the retinoblastoma protein. EMBO J 13:2897-903.
Hagemeier, C. , Walker, S. , Caswell , R. , Kourzarides, T. , Sinclair, J.
1992. The human cytomegalovirus 80-kilodalton but not the 72-kilodalton
immediate early gene transactivates heterologous promoters in a TATA
box independent mechanism and interacts directly with TFIID. J Virol
66:4452-4456.
Harbour, J. W. , and D. C. Dean. 2000. The Rb/E2F pathway: expanding
roles and emerging paradigms. Genes Dev 14:2393-409.
Harper, J. W. , G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge.
1993. The p21 Cdk- interacting protein Cip1 is a potent inhibitor of 
cyclin- dependent kinases. Cell 75:805-16.
58.
59.
60.
61.
62.
147
Haupt, Y. , R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the
rapid degradation of p53. Nature 387:296-
Hayhurst, G. P. , L. A. Bryant, R. C. Caswell, S. M. Walker, and J. H.
Sinclair. 1995. CCAA T box-dependent activation of the TAT A- less human
DNA polymerase alpha promoter by the human cytomegalovirus 72-
kilodalton major immediate-early protein. J ViroI69:182-
Hendrix, M. G., M. M. Salimans, C. P. van Boven, and C. A.
Bruggeman. 1990. High prevalence of latently present cytomegalovirus in
arterial walls of patients suffering from grade III atherosclerosis. Am J
Pathol 136:23-
Ho, M. 1982. Cytomegalovirus: Biology & Infection. Plenum Medical Book
Company, New York.
Hobbs, W. E., 2nd, and N. A. DeLuca. 1999. Perturbation of cell cycle
progression and cellular gene expression as a function of herpes simplex
virus ICPO. J Virol 73:8245-55.
63. Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a
ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420:25-
64. Horvath , R., J. Cerny, J. Benedik, Jr. , J. Hokl, I. Jelinkova, and J.
Benedik. 2000. The possible role of human cytomegalovirus (HCMV) in
the origin of atherosclerosis. J Clin Viro116: 17 -24.
65. Ishov, A. M. , and G. G. Maul. 1996. The periphery of nuclear domain 10
(ND10) as site of DNA virus deposition. J Cell Bioi 134:815-26.
66.
67.
68.
69.
70.
71.
148
Ishov, A. M. , R. M. Stenberg, and G. G. Maul. 1997. Human
cytomegalovirus immediate early interaction with host nuclear structures:
definition of an immediate transcript environment. J Cell Bioi 138:5- 16.
Iskenderian , A. C. , L. Huang, A. Reily, R. M. Stenberg, and D. 
Anders. 1996. Four of eleven loci required for transient complementation
of human cytomegalovirus DNA replication cooperate to activate
expression of replication genes. J Virol 70:383-92.
Jamieson , A. T. , G. A. Gentry, and J. H. Subak-Sharpe. 1974. Induction
of both thymidine and deoxycytidine kinase activity by herpes viruses. J
Gen Virol 24:465-80.
Jault, F. M., J. M. Jault, F. Ruchti , E. A. Fortunato, C. Clark, J. Corbeil,
D. D. Richman , and D. H. Spector. 1995. Cytomegalovirus infection
induces high levels of cyclins , phosphorylated Rb , and p53 , leading to cell
cycle arrest. J Virol 69:6697-704.
Johnson , D. , Schwarz, JK. , Cress, WD., Nevins, JR. 1993. Expression
of transcription factor E2F1 induces quiescent cells to enter S-phase.
Nature 378:206-208.
Johnson, R. A., A. D. Yurochko, E. E. Poma, L. Zhu, and E. S. Huang.
1999. Domain mapping of the human cytomegalovirus IE1-72 and cellular
p107 protein-protein interaction and the possible functional consequences.
J Gen ViroI80:1293-303.
72.
73.
74.
75.
76.
77.
149
Jupp, R., Hoffman, S., Depto, A. , Stenberg, RM., Ghazal, P. , Nelson,
JA. 1993. Direct interaction of the human cytomegalovirus IE86 protein
with the cis repression signal does not preclude TBP from binding to the
TATA box. J Virol 67:5595-5604.
Jupp, R., S. Hoffmann , R. M. Stenberg, J. A. Nelson, and P. Ghazal.
1993. Human cytomegalovirus IE86 protein interacts with promoter-bound
TAT A- binding protein via a specific region distinct from the
autorepression domain. J Virol 67:7539-46.
Kalejta, R. F. , and T. Shenk. 2002. Manipulation of the cell cycle by
human cytomegalovirus. Front Biosci 7:d295-306.
Kamijo, T. , J. D. Weber, G. Zambetti , F. Zindy, M. F. Roussel , and C. J.
Sherr. 1998. Functional and physical interactions of the ARF tumor
suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95:8292-
Kanamori , M. , M. Tajima, Y. Satoh, Y. Hoshikawa, Y. Miyazawa, K.
Okinaga, T. Kurata, and T. Sairenji. 2000. Differential effect of TPA on
cell growth and Epstein-Barr virus reactivation in epithelial cell lines
derived from gastric tissues and B cell line Raji. Virus Genes 20: 117 -25.
Kerry, J. A. , A. Sehgal , S. W. Barlow, V. J. Cavanaugh , K. Fish, J. A.
Nelson , and R. M. Stenberg. 1995. Isolation and characterization of a
low-abundance splice variant from the human cytomegalovirus major
immediate-early gene region. J Virol 69:3868-72.
78.
79.
80.
81.
82.
83.
150
Kieft, E. , and A. B. Rickinson. 2001. Epstein-Barr Virus and Its
Replication , p. 2511-2573. In D. M. Knipe and P. M. Howley (ed. ), Fields
Virology, 4th ed , vol. 2. Lippincott Williams & Wilkins , Philadelphia , PA.
Kim, S. , S. S. Yu, I. S. Lee, S. Ohno, J. Yim , and H. S. Kang. 1999.
Human cytomegalovirus IE1 protein activates AP-1 through a cellular
protein kinase(s). J Gen Virol 80:961-
Klucher, K. M., M. Sommer, J. T. Kadonaga, and D. H. Spector. 1993.
In vivo and in vitro analysis of transcriptional activation mediated by the
human cytomegalovirus major immediate-early proteins. Mol Cell Bioi
13: 1238-50.
Kowalik, T. , DeGregori , J. , Schwarz, JK. , Nevins, JR. 1995. E2F1
overexpression in quiescent fibroblasts leads to induction of cellular DNA
synthesis and apoptosis. J Virol 69:2491-2500.
Kowalik, T. F. , J. DeGregori, G. Leone, L. Jakoi , and J. R. Nevins.
1998. E2F1-specific induction of apoptosis and p53 accumulation , which is
blocked by Mdm2. Cell Growth Differ 9:113-
Kowalik, T. F., B. Wing, J. S. Haskil , J. C. Azizkhan, A. S. Baldwin,
Jr. , and E. S. Huang. 1993. Multiple mechanisms are implicated in the
regulation of NF-kappa B activity during human cytomegalovirus infection.
Proc Natl Acad Sci USA 90:1107-11.
87.
88.
89.
90.
151
84. Li, M. , H. Lee , D. W. Yoon, J. C. Albrecht, B. Fleckenstein, F. Neipel
and J. U. Jung. 1997. Kaposi's sarcoma-associated herpesvirus encodes
a functional cyclin. J Virol 71 :1984-91.
85. Lomax, M. , and M. Fried. 2001. Polyoma virus disrupts ARF signaling to
p53. Oncogene 20:4951-60.
86. Lomonte, and R. D. Everett. 1999. Herpes simplex virus type 
immediate-early protein Vmw11 0 inhibits progression of cells through
mitosis and from G(1) into S phase of the cell cycle. J ViroI73:9456-67.
Lowe, S. W. , and H. E. Ruley. 1993. Stabilization of the p53 tumor
suppressor is induced by adenovirus 5 E1A and accompanies apoptosis.
Genes Dev 7:535-45.
, M. , and T. Shenk. 1996. Human cytomegalovirus infection inhibits cell
cycle progression at multiple points , including the transition from G1 to S.
J Virol 70:8850-
, M. , and T. Shenk. 1999. Human cytomegalovirus UL69 protein
induces cells to accumulate in G1 phase of the cell cycle. J ViroI73:676-
83.
Lukac, D. M., and J. C. Alwine. 1999. Effects of human cytomegalovirus
major immediate-early proteins in controlling the cell cycle and inhibiting
apoptosis: studies with ts13 cells. J ViroI73:2825-31.
93.
94.
95.
96.
97.
152
91. Lukac, D. M. , N. Y. Harel , N. Tanese, and J. C. Alwine. 1997. TAF-like
functions of human cytomegalovirus immediate-early proteins. J Virol
71 :7227-39.
92. Malone, C. L. , D. H. Vesole, and M. F. Stinski. 1990. Transactivation of
a human cytomegalovirus early promoter by gene products from the
immediate-early gene IE2 and augmentation by IE1: mutational analysis of
the viral proteins. J Virol 64:1498-506.
Marchini , A., H. Liu , and H. Zhu. 2001. Human cytomegalovirus with IE-
(UL 122) deleted fails to express early lytic genes. J Virol 75: 1870-
Margolis , M. J. , S. Pajovic, E. L. Wong, M. Wade, R. Jupp, J. A.
Nelson, and J. C. Azizkhan. 1995. Interaction of the 72-kilodalton human
cytomegalovirus IE1 gene product with E2F1 coincides with E2F-
dependent activation of dihydrofolate reductase transcription. J Virol
69:7759-67.
Maul , G. G. , D. Negorev, P. Bell , and A. M. Ishov. 2000. Review:
properties and assembly mechanisms of ND1 0 , PML bodies , or PODs. J
Struct Bioi 129:278-87.
McCarthy, S. A. , H. S. Symonds, and T. Van Dyke. 1994. Regulation of
apoptosis in transgenic mice by simian virus 40 T antigen- mediated
inactivation of p53. Proc Natl Acad Sci USA 91 :3979-83.
Melnick, J. L. , E. Adam , and M. E. DeBakey. 1995. Cytomegalovirus and
atherosclerosis. Bioessays 17:899-903.
153
98. Melnick, J. L., B. L. Petrie, G. R. Dreesman, J. Burek, C. H. McCollum,
and M. E. DeBakey. 1983. Cytomegalovirus antigen within human arterial
smooth muscle cells. Lancet 2:644-
99. Michelson , S., P. Dal Monte, D. Zipeto, B. Bodaghi, L. Laurent, E.
Oberlin, F. Arenzana-Seisdedos, J. L. Virelizier, and M. P. Landini.
1997. Modulation of RANTES production by human cytomegalovirus
infection of fibroblasts. J Virol 71 :6495-500.
100. Minson, A. C., A. Davison, R. Eberle, R. C. Desrosiers, B.
Fleckenstein, D. J. McGeoch , B. Roizman , and D. M. J. Studdert.
2000. Family Herpesviridae p. pp. 203-225. In M. H. V. van Regenmortel
C. M. Fauquet , and D. H. L. Bishop (ed. ), Virus Taxonomy. Seventh
Report of the International Committee on Taxonomy of Viruses. Academic
Press , San Diego.
101. Mocarski, E. S. , G. W. Kemble, J. M. Lyle, and R. F. Greaves. 1996. A
deletion mutant in the human cytomegalovirus gene encoding IE1(491aa)
is replication defective due to a failure in autoregulation. Proc Natl Acad
Sci USA 93:11321-
102. Mocarski, J. E. S., and C. T. Courcelle. 2001. Cytomegaloviruses and
Their Replication , p. 2629-2673. In D. M. Knipe and P. M. Howley (ed.
Fields Virology, 4th ed, vol. 2. Lippincott Williams & Wilkins, Philadelphia
PA.
154
103. Muganda, P., R. Carrasco, and Q. Qian. 1998. The human
cytomegalovirus IE2 86 kDa protein elevates p53 levels and transactivates
the p53 promoter in human fibroblasts. Cell Mol Bioi (Noisy-Ie-grand)
44:321-31.
104. Muganda, P. , O. Mendoza, J. Hernandez, and Q. Qian. 1994. Human
cytomegalovirus elevates levels of the cellular protein p53 in infected
fibroblasts. J Virol 68:8028-34.
105. Murphy, E. A. , D. N. Streblow, J. A. Nelson, and M. F. Stinski. 2000.
The human cytomegalovirus IE86 protein can block cell cycle progression
after inducing transition into the S phase of permissive cells. J Virol
74:7108- 18.
106. Muzyczka, N. , and K. J. Berns. 2001. Parvoviridae : The Viruses and
Their Replication , p. 2327-2359. In D. M. Knipe and P. M. Howley (ed.
Fields Virology, 4th ed , vol. 2. Lippincott Williams & Wilkins, Philadelphia
PA.
107. Nakagawa, K. , Y. Taya, K. Tarnai , and M. Yarnaizurni. 1999.
Requirement of A TM in phosphorylation of the human p53 protein at
serine 15 following DNA double-strand breaks. Mol Cell Bioi 19:2828-34.
108. Nevins, J. R. 2001. Cell Transformation by Viruses, p. 245-283. In D. M.
Knipe and P. M. Howley (ed. ), Fields Virology, 4th ed , vol. 1. Lippincott
Williams & Wilkins , Philadelphia , PA.
155
109. Nevins, J. R. 1998. Toward an understanding of the functional complexity
of the E2F and retinoblastoma families. Cell Growth Differ 9:585-93.
110. Nevins, J. R., J. DeGregori, L. Jakoi , and G. Leone. 1997. Functional
analysis of E2F transcription factor. Methods Enzymol 283:205- 19.
111. Pajovic, S., E. L. Wong, A. R. Black , and J. C. Azizkhan. 1997.
Identification of a viral kinase that phosphorylates specific E2Fs and
pocket proteins. Mol Cell Bioi 17:6459-64.
112. Pampou, S., S. N. Gnedoy, V. B. Bystrevskaya, V. N. Smirnov , E. 
Chazov, J. L. Melnick, and M. E. DeBakey. 2000. Cytomegalovirus
genome and the immediate-early antigen in cells of different layers of
human aorta. Virchows Arch 436:539-52.
113. Pass, R. F. 2001. Cytomegalovirus, p. 2575-2705. In D. M. Knipe and P.
M. Howley (ed. ), Fields Virology, 4th ed, vol. 2. Lippincott Williams &
Wilkins, Philadelphia , PA.
114. Pizzorno, M. C. , and G. S. Hayward. 1990. The IE2 gene products of
human cytomegalovirus specifically down- regulate expression from the
major immediate-early promoter through a target sequence located near
the cap site. J Virol 64:6154-65.
115. Pizzorno, M. C., M. A. Mullen, Y. N. Chang, and G. S. Hayward. 1991.
The functionally active IE2 immediate-early regulatory protein of human
cytomegalovirus is an 80-kilodalton polypeptide that contains two distinct
156
activator domains and a duplicated nuclear localization signal. J Virol
65:3839-52.
116. Poma, E. E. , T. F. Kowalik, L. Zhu , J. H. Sinclair, and E. S. Huang.
1996. The human cytomegalovirus IE1-72 protein interacts with the
cellular p1 07 protein and relieves p1 07 -mediated transcriptional
repression of an E2F-responsive promoter. J ViroI70:7867-77.
117. Pomerantz , J. , Schreiber-Agus, N., Liegeois, NJ. , Silverman, A.
Alland , L. , Chin, L. , Potes, J. , Chen, K. , Orlow, I., Lee, HW., Cordon-
Cardo, C. , DePinho , RA. 1998. The Ink4a tumor suppressor gene
product , p19ARF , interacts with MDM-2 and neutralizes MDM-
inhibition of p53. Cell 92:713-723.
118. Prives, C. , and P. A. Hall. 1999. The p53 pathway. J PathoI187:112-26.
119. Rodriguez, A., E. J. Jung, and E. K. Flemington. 2001. Cell cycle
analysis of Epstein-Barr virus- infected cells following treatment with lytic
cycle- inducing agents. J Virol 75:4482-
120. Rogoff, H. A. , M. T. Pickering, M. E. Debatis, S. Jones, and T. F.
Kowalik. 2002. E2F1 Induces Phosphorylation of p53 That Is Coincident
with p53 Accumulation and Apoptosis. Mol Cell Bioi 22:5308- 18.
121. Roizman , B. , and P. E. Pellett. 2001. The Family Herpesviridae: A Brief
Introduction , p. 2381-2397. In D. M. Knipe and P. M. Howley (ed. ), Fields
Virology, 4th ed , vol. 2. Lippincott Williams & Wilkins , Philadelphia , PA.
157
122. Roizmann, B. , R. C. Desrosiers , B. Fleckenstein, C. Lopez, A. C.
Minson, and M. J. Studdert. 1992. The family Herpesviridae: an update.
The Herpesvirus Study Group of the International Committee on
Taxonomy of Viruses. Arch ViroI123:425-49.
123. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the
1990s. Nature 362:801-
124. Roth , J. , M. Dobbelstein, D. A. Freedman, T. Shenk, and A. J. Levine.
1998. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the
levels of the p53 protein via a pathway used by the human
immunodeficiency virus rev protein. EMBO J 17:554-64.
125. Sarkaria, J. N. , E. C. Busby, R. S. Tibbetts , P. Roos, Y. Taya, L. M.
Karnitz, and R. T. Abraham. 1999. Inhibition of ATM and ATR kinase
activities by the radiosensitizing agent, caffeine. Cancer Res 59:4375-82.
126. Sarnow, P. , Y. S. Ho, J. Willams , and A. J. Levine. 1982. Adenovirus
E1 b-58kd tumor antigen and SV40 large tumor antigen are physically
associated with the same 54 kd cellular protein in transformed cells. Cell
28:387 -94.
127. Schang, L. M. , J. Philips , and P. A. Schaffer. 1998. Requirement for
cellular cyclin-dependent kinases in herpes simplex virus replication and
transcription. J Virol 72:5626-37.
158
128. Scheffner, M. , B. A. Werness, J. M. Huibregtse , A. J. Levine, and P. M.
Howley. 1990. The E6 oncoprotein encoded by human papillomavirus
types 16 and 18 promotes the degradation of p53. Cell 63: 1129-36.
129. Schwartz , R. , M. H. Sommer, A. Scully, and D. H. Spector. 1994. Site-
specific binding of the human cytomegalovirus IE2 86-kilodalton protein to
an early gene promoter. J Virol 68:5613-22.
130. Shen , C. Y., M. S. Ho, S. F. Chang, M. S. Yen, H. T. Ng, E. S. Huang,
and C. W. Wu. 1993. High rate of concurrent genital infections with
human cytomegalovirus and human papillomaviruses in cervical cancer
patients. J Infect Dis 168:449-52.
131. Shen , Y. , H. Zhu, and T. Shenk. 1997. Human cytomagalovirus IE1 and
IE2 proteins are mutagenic and mediate "hit-and-run" oncogenic
transformation in cooperation with the adenovirus E1A proteins. Proc Natl
Acad Sci USA 94:3341-
132. Sinclair, J. , J. Baille, L. Bryant, and R. Caswell. 2000. Human
cytomegalovirus mediates cell cycle progression through G(1) into early S
phase in terminally differentiated cells. J Gen Virol 81 pt 6:1553-65.
133. Sinzger, C. , and G. Jahn. 1996. Human cytomegalovirus cell tropism and
pathogenesis. Intervirology 39:302- 19.
134. Song, B., J. J. Liu , K. C. Yeh , and D. M. Knipe. 2000. Herpes simplex
virus infection blocks events in the G1 phase of the cell cycle. Virology
267:326-34.
159
135. Song, B. , K. C. Yeh , J. Liu, and D. M. Knipe. 2001. Herpes simplex virus
gene products required for viral inhibition of expression of G1-phase
functions. Virology 290:320-
136. Song, Y., and M. F. Stinski. 2002. Effect of the Human Cytomegalovirus
IE86 Protein on Expression of E2F Responsive Genes: A DNA Microarray
Analysis. Proc Natl Acad Sci USA 99:2836-41.
137. Sorlie, P. D. , F. J. Nieto, E. Adam , A. R. Folsom , E. Shahar, and M.
Massing. 2000. A prospective study of cytomegalovirus , herpes simplex
virus 1 , and coronary heart disease: the atherosclerosis risk in
communities (ARIC) study. Arch Intern Med 160:2027-32.
138. Speir, E. 2000. Cytomegalovirus gene regulation by reactive oxygen
species. Agents in atherosclerosis. Ann NY Acad Sci 899:363-74.
139. Speir, E. , E. S. Huang, R. Modali , M. B. Leon , F. Shawl , T. Finkel , and
S. E. Epstein. 1995. Interaction of human cytomegalovirus with p53:
possible role in coronary restenosis. Scand J Infect Dis Suppl 99:78-81.
140. Speir, E., R. Modali , E. S. Huang, M. B. Leon , F. Shawl , T. Finkel, and
S. E. Epstein. 1994. Potential role of human cytomegalovirus and p53
interaction in coronary restenosis. Science 265:391-
141. Speir, E. , Z. X. Yu, K. Takeda, V. J. Ferrans, and R. O. Cannon , 3rd.
2000. Antioxidant effect of estrogen on cytomegalovirus-induced gene
expression in coronary artery smooth muscle cells. Circulation 102:2990-
160
142. St. Jeor, S. C. , T. B. Albrecht, F. D. Funk, and F. Rapp. 1974.
Stimulation of Cellular DNA Synthesis by Human Cytomegalovirus. J Virol
13:353-362.
143. Steinhoff, G., X. M. You , C. Steinmuller, K. Boeke, F. S. Stals, C. A.
Bruggeman , and A. Haverich. 1995. Induction of endothelial adhesion
molecules by rat cytomegalovirus in allogeneic lung transplantation in the
rat. Scand J Infect Dis Suppl 99:58-60.
144. Stenberg, R. M., D. R. Thomsen , and M. F. Stinski. 1984. Structural
analysis of the major immediate early gene of human cytomegalovirus. J
ViroI49:190-
145. Stenberg, R. M. , P. R. Witte, and M. F. Stinski. 1985. Multiple spliced
and unspliced transcripts from human cytomegalovirus immediate-early
region 2 and evidence for a common initiation site within immediate-early
region 1. J Virol 56:665-75.
146. Stinski , M. F., D. R. Thomsen , R. M. Stenberg, and L. C. Goldstein.
1983. Organization and expression of the immediate early genes of
human cytomegalovirus. J ViroI46:1- 14.
147. Stommel, J. M. , N. D. Marchenko, G. S. Jimenez, U. M. Moll , T. J.
Hope , and G. M. Wahl. 1999. A leucine-rich nuclear export signal in the
p53 tetramerization domain: regulation of subcellular localization and p53
activity by NES masking. EMBO J 18:1660-72.
161
148. Streblow, D. N. , C. Soderberg-Naucler, J. Vieira, P. Smith, E.
Wakabayashi , F. Ruchti , K. Mattison , Y. Altschuler, and J. A. Nelson.
1999. The Human Cytomegalovirus Chemokine Receptor US28 Mediates
Vascular Smooth Muscle Cell Migration. Cell 99:511-520.
149. Swenson , J. J. , A. E. Mauser, W. K. Kaufmann , and S. C. Kenney.
1999. The Epstein-Barr virus protein BRLF1 activates S phase entry
through E2F1 induction. J Virol 73:6540-50.
150. Tao , W. , and A. J. Levine. 1999. Nucleocytoplasmic shuttling of
oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53.
Proc Natl Acad Sci USA 96:3077-80.
151. Trimarchi , J. M. , and J. A. Lees. 2002. Transcriptionsibling rivalry in the
e2f family. Nat Rev Mol Cell Bioi 3: 11-20.
152. Tsai , H. L. , G. H. Kou, S. C. Chen, C. W. Wu , and Y. S. Un. 1996.
Human cytomegalovirus immediate-early protein IE2 tethers a
transcriptional repression domain to p53. J Bioi Chem 271 :3534-40.
153. Vousden , K. H. 2002. Activation of the p53 tumor suppressor protein.
Biochim Biophys Acta 1602:47-59.
154. Vousden , K. H. , and X. Lu. 2002. Live or let die: the cell's response to
p53. Nat Rev Cancer 2:594-604.
155. Vousden , K. H. , and G. F. Woude. 2000. The ins and outs of p53. Nat
Cell Bioi 2:E178-80.
162
156. Walker, S., C. Hagemeier, J. G. Sissons, and J. H. Sinclair. 1992. A 10-
base-pair element of the human immunodeficiency virus type 1 long
terminal repeat (L TR) is an absolute requirement for transactivation by the
human cytomegalovirus 72-kilodalton IE1 protein but can be compensated
for by other L TR regions in transactivation by the 80- kilodalton IE2
protein. J Virol 66: 1543-50.
157. Wathen, M. W. , and M. F. Stinski. 1982. Temporal patterns of human
cytomegalovirus transcription: mapping the viral RNAs synthesized at
immediate early, early, and late times after infection. J Virol 41 :462-77.
158. Weber, J. D. , L. J. Taylor, M. F. Roussel , C. J. Sherr, and D. Bar-Sagi.
1999. Nucleolar Art sequesters Mdm2 and activates p53. Nat Cell Bioi
1 :20-
159. White , D. , and F. L. Fenner. 1994. Herpesviridae , p. 317-347. In D. O.
White (ed. ), Medical Virology, 4th ed. Academic Press , Inc. , San Diego
CA.
160. Wiebusch, L. , and C. Hagemeier. 2001. The human cytomegalovirus
immediate early 2 protein dissociates cellular DNA synthesis from cyclin-
dependent kinase activation. EMBO J 20:1086-98.
161. Xiong, Y. , G. J. Hannon , H. Zhang, D. Casso, R. Kobayashi, and D.
Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature
366:701-
163
162. Yeung, K. C., C. M. Stoltzfus, and M. F. Stinski. 1993. Mutations of the
human cytomegalovirus immediate-early 2 protein defines regions and
amino acid motifs important in transactivation of transcription from the
HIV-1 L TR promoter. Virology 195:786-92.
163. Yew, P. R. , and A. J. Berk. 1992. Inhibition of p53 transactivation
required for transformation by adenovirus early 1 B protein. Nature 357:82-
164. Yurochko, A. D. , T. F. Kowalik, S. M. Huong, and E. S. Huang. 1995.
Human cytomegalovirus upregulates NF-kappa B activity by
transactivating the NF-kappa B p105/p50 and p65 promoters. J Virol
69:5391-400.
165. Yurochko, A. D. , M. W. Mayo, E. E. Poma, A. S. Baldwin , Jr. , and E. S.
Huang. 1997. Induction of the transcription factor Sp1 during human
cytomegalovirus infection mediates upregulation of the p65 and p105/p50
NF-kappaB promoters. J Virol 71 :4638-48.
166. Zacny, V. L. , J. Wilson, and J. S. Pagano. 1998. The Epstein-Barr virus
immediate-early gene product , BRLF1 , interacts with the retinoblastoma
protein during the viral lytic cycle. J Virol 72:8043-51.
167. Zhang, Q., D. Gutsch , and S. Kenney. 1994. Functional and physical
interaction between p53 and BZLF1: implications for Epstein-Barr virus
latency. Mol Cell Bioi 14:1929-38.
164
168. Zhang, Y. , and Y. Xiong. 1999. Mutations in human ARF exon 2 disrupt
its nucleolar localization and impair its ability to block nuclear export of
MDM2 and pS3. Mol Cell 3:S79-91.
169. Zhang, Y., and Y. Xiong. 2001. A pS3 amino-terminal nuclear export
signal inhibited by DNA damage- induced phosphorylation. Science
292: 191 O-
170. Zhang, Y., Y. Xiong, and W. G. Yarbrough. 1998. ARF promotes MDM2
degradation and stabilizes p53: ARF- INK4a locus deletion impairs both
the Rb and pS3 tumor suppression pathways. Cell 92:72S-34.
171. Zhou, B. B. , and S. J. Elledge. 2000. The DNA damage response:
putting checkpoints in perspective. Nature 408:433-
172. Zhou, Y. F., E. Guetta
, Z. X. Yu, T. Finkel, and S. E. Epstein. 1996.
Human cytomegalovirus increases modified low density lipoprotein uptake
and scavenger receptor mRNA expression in vascular smooth muscle
cells. J Clin Invest 98:2129-38.
173. Zhou , Y. F. , M. B. Leon , M. A. Waclawiw, J. J. Popma, Z. X. Yu , T.
Finkel , and S. E. Epstein. 1996. Association between prior
cytomegalovirus infection and the risk of restenosis after coronary
atherectomy. N Engl J Med 335:624-30.
174. Zhou, Y. F. , M. Shou, R. F. Harrell , Z. X. Yu, E. F. Unger, and S. E.
Epstein. 2000. Chronic non-vascular cytomegalovirus infection: effects on
165
the neointimal response to experimental vascular injury. Cardiovasc Res
45: 1 019-25.
175. Zhou, Y. F. , Z. X. Yu, C. Wanishsawad , M. Shou , and S. E. Epstein.
1999. The immediate early gene products of human cytomegalovirus
increase vascular smooth muscle cell migration
, proliferation , and
expression of PDGF beta-receptor. Biochem Biophys Res Commun
256:608- 13.
176. Zhu , H. , Y. Shen , and T. Shenk. 1995. Human cytomegalovirus IE1 and
IE2 proteins block apoptosis. J Virol 69:7960-70.
177. Zhu, L., S. van den Heuvel , K. Helin , A. Fattaey, M. Ewen , D.
Livingston, N. Dyson, and E. Harlow. 1993. Inhibition of cell proliferation
by p1 07 , a relative of the retinoblastoma protein. Genes Dev 7:1111-25.
